|
1
|
Leaf C: Why we're losing the war on cancer
(and how to win it). Fortune. 149:76–82. 84–86. 882004.PubMed/NCBI
|
|
2
|
Debela DT, Muzazu SG, Heraro KD, Ndalama
MT, Mesele BW, Haile DC, Kitui SK and Manyazewal T: New approaches
and procedures for cancer treatment: Current perspectives. SAGE
Open Med. 9:205031212110343662021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ke X and Shen L: Molecular targeted
therapy of cancer: The progress and future prospect. Front
Laboratory Med. 1:69–75. 2017. View Article : Google Scholar
|
|
4
|
Liang XJ, Chen C, Zhao Y and Wang PC:
Circumventing tumor resistance to chemotherapy by nanotechnology.
Methods Mol Biol. 596:467–488. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iyer AK, Khaled G, Fang J and Maeda H:
Exploiting the enhanced permeability and retention effect for tumor
targeting. Drug Discov Today. 11:812–818. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Szabo C: Gasotransmitters in cancer: From
pathophysiology to experimental therapy. Nat Rev Drug Discov.
15:185–203. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu W, Liu LZ, Loizidou M, Ahmed M and
Charles IG: The role of nitric oxide in cancer. Cell Res.
12:311–320. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ngowi EE, Afzal A, Sarfraz M, Khattak S,
Zaman SU, Khan NH, Li T, Jiang QY, Zhang X, Duan SF, et al: Role of
hydrogen sulfide donors in cancer development and progression. Int
J Biol Sci. 17:73–88. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hellmich MR and Szabo C: Hydrogen sulfide
and cancer. Handb Exp Pharmacol. 230:233–241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wegiel B, Gallo D, Csizmadia E, Harris C,
Belcher J, Vercellotti GM, Penacho N, Seth P, Sukhatme V, Ahmed A,
et al: Carbon monoxide expedites metabolic exhaustion to inhibit
tumor growth. Cancer Res. 73:7009–7021. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vannini F, Kashfi K and Nath N: The dual
role of iNOS in cancer. Redox Biol. 6:334–343. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kashfi K: The dichotomous role of
H2S in cancer cell biology? Déjà vu all over again.
Biochem Pharmacol. 149:205–223. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tien Vo TT, Vo QC, Tuan VP, Wee Y, Cheng
HC and Lee IT: The potentials of carbon monoxide-releasing
molecules in cancer treatment: An outlook from ROS biology and
medicine. Redox Biol. 46:1021242021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gensini GF, Conti AA and Lippi D: The
contributions of Paul Ehrlich to infectious disease. J Infection.
54:221–224. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Riddell S: The emperor of all maladies: A
biography of cancer. J Clin Invest. 121:52011. View Article : Google Scholar
|
|
16
|
Bosch F and Rosich L: The contributions of
Paul Ehrlich to pharmacology: A tribute on the occasion of the
centenary of his Nobel Prize. Pharmacology. 82:171–179. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Valent P, Groner B, Schumacher U,
Superti-Furga G, Busslinger M, Kralovics R, Zielinski C, Penninger
JM, Kerjaschki D, Stingl G, et al: Paul Ehrlich (1854–1915) and his
contributions to the foundation and birth of translational
medicine. J Innate Immun. 8:111–120. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Faguet GB: A brief history of cancer:
Age-old milestones underlying our current knowledge database. Int J
Cancer. 136:2022–2036. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baselga J, Bhardwaj N, Cantley LC,
DeMatteo R, DuBois RN, Foti M, Gapstur SM, Hahn WC, Helman LJ,
Jensen RA, et al: AACR cancer progress report 2015. Clin Cancer
Res. 21 (Suppl 19):S1–S128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Farber S and Diamond LK: Temporary
remissions in acute leukemia in children produced by folic acid
antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med.
238:787–793. 1948. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kotecha RS, Gottardo NG, Kees UR and Cole
CH: The evolution of clinical trials for infant acute lymphoblastic
leukemia. Blood Cancer J. 4:e2002014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kinjo J, Nakano D, Fujioka T and Okabe H:
Screening of promising chemotherapeutic candidates from plants
extracts. J Nat Med. 70:335–360. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Freireich EJ, Karon M and Frei III E:
Quadruple combination therapy (VAMP) for acute lymphocytic leukemia
of childhood. Proc Am Assoc Cancer Res. 5:201964.
|
|
24
|
Liebman HA, Hum GJ, Sheehan WW, Ryden VM
and Bateman JR: Randomized study for the treatment of adult
advanced Hodgkin's disease: Mechlorethamine, vincristine,
procarbazine, and prednisone (MOPP) versus lomustine, vinblastine,
and prednisone. Cancer Treat Rep. 67:413–419. 1983.PubMed/NCBI
|
|
25
|
Bonadonna G, Zucali R, Monfardini S, De
Lena M and Uslenghi C: Combination chemotherapy of Hodgkin's
disease with adriamycin, bleomycin, vinblastine, and imidazole
carboxamide versus MOPP. Cancer. 36:252–259. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arruebo M, Vilaboa N, Sáez-Gutierrez B,
Lambea J, Tres A, Valladares M and González-Fernández A: Assessment
of the evolution of cancer treatment therapies. Cancers (Basel).
3:3279–3330. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bonadonna G, Valagussa P, Moliterni A,
Zambetti M and Brambilla C: Adjuvant cyclophosphamide,
methotrexate, and fluorouracil in node-positive breast cancer: The
results of 20 years of follow-up. N Engl J Med. 332:901–906. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fisher B, Sherman B, Rockette H, Redmond
C, Margolese R and Fisher ER: 1-phenylalanine mustard (L-PAM) in
the management of premenopausal patients with primary breast
cancer: lack of association of disease-free survival with
depression of ovarian function. National Surgical Adjuvant Project
for Breast and Bowel Cancers. Cancer. 44:847–857. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), . Long-term outcomes for neoadjuvant
versus adjuvant chemotherapy in early breast cancer: Meta-analysis
of individual patient data from ten randomised trials. Lancet
Oncol. 19:27–39. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mansoori B, Mohammadi A, Davudian S,
Shirjang S and Baradaran B: The different mechanisms of cancer drug
resistance: A Brief Review. Adv Pharm Bull. 7:339–348. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Roma-Rodrigues C, Mendes R, Baptista PV
and Fernandes AR: Targeting tumor microenvironment for cancer
therapy. Int J Mol Sci. 20:8402019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bagnyukova TV, Serebriiskii IG, Zhou Y,
Hopper-Borge EA, Golemis EA and Astsaturov I: Chemotherapy and
signaling: How can targeted therapies supercharge cytotoxic agents?
Cancer Biol Ther. 10:839–853. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Whiteside TL: The tumor microenvironment
and its role in promoting tumor growth. Oncogene. 27:5904–5912.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Alkasalias T, Moyano-Galceran L,
Arsenian-Henriksson M and Lehti K: Fibroblasts in the Tumor
Microenvironment: Shield or Spear? Int J Mol Sci. 19:15322018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Klemm F and Joyce JA: Microenvironmental
regulation of therapeutic response in cancer. Trends Cell Biol.
25:198–213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vaupel P and Multhoff G:
Hypoxia-/HIF-1α-Driven factors of the tumor microenvironment
impeding antitumor immune responses and promoting malignant
progression. Adv Exp Med Biol. 1072:171–175. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jing X, Yang F, Shao C, Wei K, Xie M, Shen
H and Shu Y: Role of hypoxia in cancer therapy by regulating the
tumor microenvironment. Mol Cancer. 18:1572019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Luo W and Wang Y: Hypoxia mediates tumor
malignancy and therapy resistance. Adv Exp Med Biol. 1136:1–18.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jarosz-Biej M, Smolarczyk R, Cichoń T and
Kułach N: Tumor Microenvironment as A ‘Game Changer’ in cancer
radiotherapy. Int J Mol Sci. 20:32122019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Befani C and Liakos P: The role of
hypoxia-inducible factor-2 alpha in angiogenesis. J Cell Physiol.
233:9087–9098. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Senthebane DA, Rowe A, Thomford NE,
Shipanga H, Munro D, Mazeedi MAMA, Almazyadi HAM, Kallmeyer K,
Dandara C, Pepper MS, et al: The role of tumor microenvironment in
chemoresistance: to survive, keep your enemies closer. Int J Mol
Sci. 18:15862017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hass R, von der Ohe J and Ungefroren H:
Impact of the tumor microenvironment on tumor heterogeneity and
consequences for cancer cell plasticity and stemness. Cancers
(Basel). 12:37162020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Vitale I, Manic G, Coussens LM, Kroemer G
and Galluzzi L: Macrophages and Metabolism in the Tumor
Microenvironment. Cell Metab. 30:36–50. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bu L, Baba H, Yoshida N, Miyake K, Yasuda
T, Uchihara T, Tan P and Ishimoto T: Biological heterogeneity and
versatility of cancer-associated fibroblasts in the tumor
microenvironment. Oncogene. 38:4887–4901. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang R: The Evolution of Gasotransmitter
Biology and Medicine. Signal Transduction and the Gasotransmitters:
NO, CO, and H2S in Biology and Medicine. Wang R: Humana Press;
Totowa, NJ: pp. 3–31. 2004, View Article : Google Scholar
|
|
46
|
Andrew PJ and Mayer B: Enzymatic function
of nitric oxide synthases. Cardiovasc Res. 43:521–531. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ryter SW and Choi AMK: Heme
oxygenase-1/carbon monoxide: From metabolism to molecular therapy.
Am J Respir Cell Mol Biol. 41:251–260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Naik JS, O'Donaughy TL and Walker BR:
Endogenous carbon monoxide is an endothelial-derived vasodilator
factor in the mesenteric circulation. Am J Physiol Heart Circ
Physiol. 284:H838–H845. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang R: The gasotransmitter role of
hydrogen sulfide. Antioxid Redox Signal. 5:493–501. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tang G, Wu L, Liang W and Wang R: Direct
stimulation of K(ATP) channels by exogenous and endogenous hydrogen
sulfide in vascular smooth muscle cells. Mol Pharmacol.
68:1757–1764. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Salihi A: Activation of inward rectifier
potassium channels in high salt impairment of hydrogen
sulfide-induced aortic relaxation in rats. Physiol Pharmacol.
19:263–273. 2016.
|
|
52
|
Wang L, Xie X, Ke B, Huang W, Jiang X and
He G: Recent advances on endogenous gasotransmitters in
inflammatory dermatological disorders. J Adv Res. (In Press).
|
|
53
|
West JB: Joseph Priestley, oxygen, and the
enlightenment. Am J Physiol Lung Cell Mol Physiol. 306:L111–L119.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gruetter CA, Barry BK, McNamara DB,
Gruetter DY, Kadowitz PJ and Ignarro L: Relaxation of bovine
coronary artery and activation of coronary arterial guanylate
cyclase by nitric oxide, nitroprusside and a carcinogenic
nitrosoamine. J Cyclic Nucleotide Res. 5:211–224. 1979.PubMed/NCBI
|
|
55
|
Furchgott RF and Zawadzki JV: The
obligatory role of endothelial cells in the relaxation of arterial
smooth muscle by acetylcholine. Nature. 288:373–376. 1980.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ignarro LJ, Buga GM, Wood KS, Byrns RE and
Chaudhuri G: Endothelium-derived relaxing factor produced and
released from artery and vein is nitric oxide. Proc Natl Acad Sci
USA. 84:9265–9269. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Palmer RM, Ferrige AG and Moncada S:
Nitric oxide release accounts for the biological activity of
endothelium-derived relaxing factor. Nature. 327:524–526. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Moncada S, Palmer RM and Higgs EA: The
discovery of nitric oxide as the endogenous nitrovasodilator.
Hypertension. 12:365–372. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Murad F, Mittal CK, Arnold WP, Katsuki S
and Kimura H: Guanylate cyclase: Activation by azide, nitro
compounds, nitric oxide, and hydroxyl radical and inhibition by
hemoglobin and myoglobin. Adv Cyclic Nucleotide Res. 9:145–158.
1978.PubMed/NCBI
|
|
60
|
Koshland DE Jr: The molecule of the year.
Science. 258:18611992. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Marsh N and Marsh A: A short history of
nitroglycerine and nitric oxide in pharmacology and physiology.
Clin Exp Pharmacol Physiol. 27:313–319. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Xu WM and Liu LZ: Nitric Oxide: Nitric
oxide: From a mysterious labile factor to the molecule of the Nobel
Prize. Recent progress in nitric oxide research. Cell Res.
8:251–258. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yetik-Anacak G and Catravas JD: Nitric
oxide and the endothelium: History and impact on cardiovascular
disease. Vascul Pharmacol. 45:268–276. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kennedy J: Account of the phænomena
produced by a large quantity of nitric oxide of quicksilver,
swallowed by mistake; and of the means employed to counteract its
deleterious influence. Med Chir J Rev. 1:189–196. 1816.PubMed/NCBI
|
|
65
|
Thomsen LL, Lawton FG, Knowles RG, Beesley
JE, Riveros-Moreno V and Moncada S: Nitric oxide synthase activity
in human gynecological cancer. Cancer Res. 54:1352–1354.
1994.PubMed/NCBI
|
|
66
|
Hidy GM, Mueller PK, Altshuler SL, Chow JC
and Watson JG: Air quality measurements-From rubber bands to
tapping the rainbow. J Air Waste Manag Assoc. 67:637–668. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kinnicutt LP and Sanford GR: The
iodometric determination of small quantities of carbon monoxide.
Public Health Pap Rep. 25:600–604. 1899.PubMed/NCBI
|
|
68
|
Luden G: THE carbon monoxide menace and
the cancer problem. Can Med Assoc J. 17:43–48. 1927.PubMed/NCBI
|
|
69
|
Roughton FJW: The Kinetics of Haemoglobin
V-The Combination of Carbon Monoxide with Reduced Haemoglobin. Proc
R Soc London Series B, Containing Papers Biol Character.
115:464–473. 1934. View Article : Google Scholar
|
|
70
|
Roughton FJW and Darling RC: The effect of
carbon monoxide on the oxyhemoglobin dissociation curve. Am J
Physiol Legacy Content. 141:17–31. 1944. View Article : Google Scholar
|
|
71
|
Roughton FJ: The equilibrium between
carbon monoxide and sheep haemoglobin at very high percentage
saturations. J Physiol. 126:359–383. 1954. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Sjostrand T: Endogenous formation of
carbon monoxide in man. Nature. 164:5801949. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Tenhunen R, Marver HS and Schmid R:
Microsomal heme oxygenase. Characterization of the enzyme. J Biol
Chem. 244:6388–6394. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhao Y, Biggs TD and Xian M: Hydrogen
sulfide (H2S) releasing agents: Chemistry and biological
applications. Chem Commun (Camb). 50:11788–11805. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Tanner FW: Studies on the bacterial
metabolism of sulfur: I. Formation of hydrogen sulfide from certain
sulfur compounds under aerobic conditions. J Bacteriol. 2:585–593.
1917. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Rose P, Moore PK, Ming SH, Nam OC,
Armstrong JS and Whiteman M: Hydrogen sulfide protects colon cancer
cells from chemopreventative agent beta-phenylethyl isothiocyanate
induced apoptosis. World J Gastroenterol. 11:3990–3997. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Wang R: Signaling pathways for the
vascular effects of hydrogen sulfide. Curr Opin Nephrol Hypertens.
20:107–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Housein Z, Kareem TS and Salihi A: In
vitro anticancer activity of hydrogen sulfide and nitric oxide
alongside nickel nanoparticle and novel mutations in their genes in
CRC patients. Sci Rep. 11:25362021. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Shen Y, Shen Z, Luo S, Guo W and Zhu YZ:
The cardioprotective effects of hydrogen sulfide in heart diseases:
From molecular mechanisms to therapeutic potential. Oxid Med Cell
Longev. 2015:9251672015. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Coleman JW: Nitric oxide in immunity and
inflammation. Int Immunopharmacol. 1:1397–1406. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Esplugues JV: NO as a signalling molecule
in the nervous system. Br J Pharmacol. 135:1079–1095. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Sen S, Jensen K, Brennan K, Ramadoss S and
Chaudhuri G: Chapter 10-Chemoprotective and chemosensitizing
effects of nitric oxide and other biologically active gases in
breast cancer chemotherapy: Potential implications. Nitric Oxide
(Donor/Induced) in Chemosensitizing. Bonavida B: Academic Press;
pp. 169–178. 2017, View Article : Google Scholar
|
|
83
|
Choudhari SK, Chaudhary M, Bagde S,
Gadbail AR and Joshi V: Nitric oxide and cancer: A review. World J
Surg Oncol. 11:1182013. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Burke AJ, Sullivan FJ, Giles FJ and Glynn
SA: The yin and yang of nitric oxide in cancer progression.
Carcinogenesis. 34:503–512. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ying L and Hofseth LJ: An Emerging role
for endothelial nitric oxide synthase in chronic inflammation and
cancer. Cancer Res. 67:1407–1410. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Tennyson Andrew G and Lippard Stephen J:
Generation, translocation, and action of nitric oxide in living
systems. Chem Biol. 18:1211–1220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Grisham MB, Jourd'Heuil D and Wink DA:
Nitric oxide. I. Physiological chemistry of nitric oxide and its
metabolites: Implications in inflammation. Am J Physiol.
276:G315–G321. 1999.PubMed/NCBI
|
|
88
|
Subapriya R, Kumaraguruparan R,
Ramachandran CR and Nagini S: Oxidant-antioxidant status in
patients with oral squamous cell carcinomas at different intraoral
sites. Clin Biochem. 35:489–493. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Cheng H, Wang L, Mollica M, Re AT, Wu S
and Zuo L: Nitric oxide in cancer metastasis. Cancer Lett. 353:1–7.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Frérart F, Sonveaux P, Rath G, Smoos A,
Meqor A, Charlier N, Jordan BF, Saliez J, Noël A, Dessy C, et al:
The acidic tumor microenvironment promotes the reconversion of
nitrite into nitric oxide: Towards a new and safe radiosensitizing
strategy. Clin Cancer Res. 14:2768–2774. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Tanese K, Grimm EA and Ekmekcioglu S: The
role of melanoma tumor-derived nitric oxide in the tumor
inflammatory microenvironment: Its impact on the chemokine
expression profile, including suppression of CXCL10. Int J Cancer.
131:891–901. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Decker NK, Abdelmoneim SS, Yaqoob U,
Hendrickson H, Hormes J, Bentley M, Pitot H, Urrutia R, Gores GJ
and Shah VH: Nitric oxide regulates tumor cell cross-talk with
stromal cells in the tumor microenvironment of the liver. Am J
Pathol. 173:1002–1012. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
PeNarando J, Aranda E and RodrIguez-Ariza
A: Immunomodulatory roles of nitric oxide in cancer: Tumor
microenvironment says ‘NO’ to antitumor immune response. Transl
Res. 210:99–108. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Arora H, Panara K, Kuchakulla M,
Kulandavelu S, Burnstein KL, Schally AV, Hare JM and Ramasamy R:
Alterations of tumor microenvironment by nitric oxide impedes
castration-resistant prostate cancer growth. Proc Natl Acad Sci
USA. 115:11298–11303. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Yang G: Hydrogen sulfide in cell survival:
A double-edged sword. Exp Rev Clin Pharmacol. 4:33–47. 2011.
View Article : Google Scholar
|
|
96
|
Pei Y, Wu B, Cao Q, Wu L and Yang G:
Hydrogen sulfide mediates the anti-survival effect of sulforaphane
on human prostate cancer cells. Toxicol Appl Pharmacol.
257:420–428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Bhattacharyya S, Saha S, Giri K, Lanza IR,
Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal
E, Weaver AL, et al: Cystathionine beta-synthase (CBS) contributes
to advanced ovarian cancer progression and drug resistance. PLoS
One. 8:e791672013. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Hellmich MR, Coletta C, Chao C and Szabo
C: The therapeutic potential of cystathionine β-synthetase/hydrogen
sulfide inhibition in cancer. Antioxid Redox Signal. 22:424–448.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Zhu H, Blake S, Chan KT, Pearson RB and
Kang J: Cystathionine β-synthase in physiology and cancer. Biomed
Res Int. 2018:32051252018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Hellmich MR and Szabo C: Hydrogen sulfide
and cancer. Chemistry, Biochemistry and Pharmacology of Hydrogen
Sulfide. Springer; New York, NY: pp. 233–241. 2015, View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Sen N: Functional and molecular insights
of hydrogen sulfide signaling and protein sulfhydration. J Mol
Biol. 429:543–561. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Chattopadhyay M, Kodela R, Nath N,
Dastagirzada YM, Velázquez-Martínez CA, Boring D and Kashfi K:
Hydrogen sulfide-releasing NSAIDs inhibit the growth of human
cancer cells: A general property and evidence of a tissue
type-independent effect. Biochem Pharmacol. 83:715–722. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Szabo C, Ransy C, Módis K, Andriamihaja M,
Murghes B, Coletta C, Olah G, Yanagi K and Bouillaud F: Regulation
of mitochondrial bioenergetic function by hydrogen sulfide. Part I.
Biochemical and physiological mechanisms. Br J Pharmacol.
171:2099–2122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Rose P, Moore PK and Zhu YZ:
H2S biosynthesis and catabolism: New insights from
molecular studies. Cell Mol Life Sci. 74:1391–1412. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Cao X, Ding L, Xie ZZ, Yang Y, Whiteman M,
Moore PK and Bian JS: A review of hydrogen sulfide synthesis,
metabolism, and measurement: Is modulation of hydrogen sulfide a
novel therapeutic for cancer? Antioxid Redox Signal. 31:1–38. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Giuffrè A, Tomé CS, Fernandes DGF, Zuhra K
and Vicente JB: Hydrogen sulfide metabolism and signaling in the
tumor microenvironment. Adv Exp Med Biol. 1219:335–353. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Wang RH, Chu YH and Lin KT: The hidden
role of hydrogen sulfide metabolism in cancer. Int J Mol Sci.
22:65622021. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Watnick RS: The role of the tumor
microenvironment in regulating angiogenesis. Cold Spring Harb
Perspect Med. 2:a0066762012. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Zhou Y, Li XH, Zhang CC, Wang MJ, Xue WL,
Wu DD, Ma FF, Li WW, Tao BB and Zhu YC: Hydrogen sulfide promotes
angiogenesis by downregulating miR-640 via the VEGFR2/mTOR pathway.
Am J Physiol Cell Physiol. 310:C305–C317. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Wang M, Yan J, Cao X, Hua P and Li Z:
Hydrogen sulfide modulates epithelial-mesenchymal transition and
angiogenesis in non-small cell lung cancer via HIF-1α activation.
Biochem Pharmacol. 172:1137752020. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Szabo C and Hellmich MR: Endogenously
produced hydrogen sulfide supports tumor cell growth and
proliferation. Cell Cycle. 12:2915–2916. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Holwerda KM, Burke SD, Faas MM, Zsengeller
Z, Stillman IE, Kang PM, van Goor H, McCurley A, Jaffe IZ,
Karumanchi SA and Lely AT: Hydrogen sulfide attenuates
sFlt1-Induced hypertension and renal damage by upregulating
vascular endothelial growth factor. J Am Soc Nephrol. 25:717–725.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Szabo C, Coletta C, Chao C, Módis K,
Szczesny B, Papapetropoulos A and Hellmich MR: Tumor-derived
hydrogen sulfide, produced by cystathionine-β-synthase, stimulates
bioenergetics, cell proliferation, and angiogenesis in colon
cancer. Proc Natl Acad Sci USA. 110:12474–12479. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Liu D, Liu M, Wan Y, Zhou X, Yang S, An L,
Huang G and Tian Q: Remodeling endogenous H2S
microenvironment in colon cancer to enhance chemodynamic therapy.
Chem Engineering J. 422:1300982021. View Article : Google Scholar
|
|
115
|
Wan M, Liu Z, Li T, Chen H, Wang Q, Chen
T, Tao Y and Mao C: Zwitterion-Based hydrogen sulfide nanomotors
induce multiple acidosis in tumor cells by destroying tumor
metabolic symbiosis. Angew Chem Int Ed Engl. 60:16139–16148. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Li D, Xiong Q, Peng J, Hu B, Li W, Zhu Y
and Shen X: Hydrogen Sulfide Up-Regulates the expression of
ATP-Binding cassette transporter A1 via promoting nuclear
translocation of PPARα. Int J Mol Sci. 17:6352016. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Schulze A and Harris AL: How cancer
metabolism is tuned for proliferation and vulnerable to disruption.
Nature. 491:3642012. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Lee ZW, Teo XY, Tay EY, Tan CH, Hagen T,
Moore PK and Deng LW: Utilizing hydrogen sulfide as a novel
anti-cancer agent by targeting cancer glycolysis and pH imbalance.
Br J Pharmacol. 171:4322–4336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Niland S, Riscanevo AX and Eble JA: Matrix
metalloproteinases shape the tumor microenvironment in cancer
progression. Int J Mol Sci. 23:1462021. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Harjunpää H, Llort Asens M, Guenther C and
Fagerholm SC: Cell adhesion molecules and their roles and
regulation in the immune and tumor microenvironment. Front Immunol.
10:10782019. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Mao Y, Keller ET, Garfield DH, Shen K and
Wang J: Stromal cells in tumor microenvironment and breast cancer.
Cancer Metastasis Rev. 32:303–315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Zhen Y, Pan W, Hu F, Wu H, Feng J, Zhang Y
and Chen J: Exogenous hydrogen sulfide exerts
proliferation/anti-apoptosis/angiogenesis/migration effects via
amplifying the activation of NF-κB pathway in PLC/PRF/5 hepatoma
cells. Int J Oncol. 46:2194–2204. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Li H, Xu F, Gao G, Gao X, Wu B, Zheng C,
Wang P, Li Z, Hua H and Li D: Hydrogen sulfide and its donors:
Novel antitumor and antimetastatic therapies for triple-negative
breast cancer. Redox Biol. 34:1015642020. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Wu D, Li M, Tian W, Wang S, Cui L, Li H,
Wang H, Ji A and Li Y: Hydrogen sulfide acts as a double-edged
sword in human hepatocellular carcinoma cells through
EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways. Sci Rep.
7:51342017. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Wu D, Li J, Zhang Q, Tian W, Zhong P, Liu
Z, Wang H, Wang H, Ji A and Li Y: Exogenous hydrogen sulfide
regulates the growth of human thyroid carcinoma cells. Oxid Med
Cell Longev. 2019:69272982019. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Zhang L, Qi Q, Yang J, Sun D, Li C, Xue Y,
Jiang Q, Tian Y, Xu C and Wang R: An anticancer role of hydrogen
sulfide in human gastric cancer cells. Oxid Med Cell Longev.
2015:6364102015. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Rose JJ, Wang L, Xu Q, McTiernan CF, Shiva
S, Tejero J and Gladwin MT: Carbon monoxide poisoning:
Pathogenesis, management, and future directions of therapy. Am J
Respir Crit Care Med. 195:596–606. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Motterlini R and Otterbein LE: The
therapeutic potential of carbon monoxide. Nat Rev Drug Discov.
9:728–743. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Wegiel B, Nemeth Z, Correa-Costa M, Bulmer
AC and Otterbein LE: Heme Oxygenase-1: A Metabolic Nike. Antioxid
Redox Signal. 20:1709–1722. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Ismailova A, Kuter D, Bohle DS and Butler
IS: An overview of the potential therapeutic applications of
CO-Releasing molecules. Bioinorg Chem Appl. 2018:85473642018.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Ji X, Damera K, Zheng Y, Yu B, Otterbein
LE and Wang B: Toward carbon monoxide-based therapeutics: Critical
drug delivery and developability issues. J Pharm Sci. 105:406–416.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
McCoubrey WK Jr, Huang T and Maines MD:
Isolation and characterization of a cDNA from the rat brain that
encodes hemoprotein heme oxygenase-3. Eur J Biochem. 247:725–732.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Otterbein LE, Soares MP, Yamashita K and
Bach FH: Heme oxygenase-1: Unleashing the protective properties of
heme. Trends Immunol. 24:449–455. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Ryter SW, Alam J and Choi AMK: Heme
Oxygenase-1/Carbon monoxide: From basic science to therapeutic
applications. Physiol Rev. 86:583–650. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Chen S, Wang X, Nisar MF, Lin M and Zhong
JL: Heme Oxygenases: Cellular multifunctional and protective
molecules against UV–Induced oxidative stress. Oxid Med Cell
Longev. 2019:54167282019. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Goebel U and Wollborn J: Carbon monoxide
in intensive care medicine-time to start the therapeutic
application? Intensive Care Med Exp. 8:22020. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Zuckerbraun BS, Chin BY, Bilban M, d'Avila
JC, Rao J, Billiar TR and Otterbein LE: Carbon monoxide signals via
inhibition of cytochrome c oxidase and generation of mitochondrial
reactive oxygen species. FASEB J. 21:1099–1106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Chin BY, Jiang G, Wegiel B, Wang HJ,
Macdonald T, Zhang XC, Gallo D, Cszimadia E, Bach FH, Lee PJ and
Otterbein LE: Hypoxia-inducible factor 1alpha stabilization by
carbon monoxide results in cytoprotective preconditioning. Proc
Natl Acad Sci USA. 104:5109–5114. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Shefa U, Yeo SG, Kim MS, Song IO, Jung J,
Jeong NY and Huh Y: Role of gasotransmitters in oxidative stresses,
neuroinflammation, and neuronal repair. Biomed Res.
2017:16893412017.PubMed/NCBI
|
|
141
|
Yang C, Jeong S, Ku S, Lee K and Park MH:
Use of gasotransmitters for the controlled release of polymer-based
nitric oxide carriers in medical applications. J Control Release.
279:157–170. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Hassan AY, Maulood IM and Salihi A: The
vasodilatory mechanism of nitric oxide and hydrogen sulfide in the
human mesenteric artery in patients with colorectal cancer. Exp
Ther Med. 21:2142021. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Konovalova NP, Goncharova SA, Volkova LM,
Rajewskaya TA, Eremenko LT and Korolev AM: Nitric oxide donor
increases the efficiency of cytostatic therapy and retards the
development of drug resistance. Nitric Oxide. 8:59–64. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Weyerbrock A, Baumer B and Papazoglou A:
Growth inhibition and chemosensitization of exogenous nitric oxide
released from NONOates in glioma cells in vitro. J Neurosurg.
110:128–136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Wink DA, Cook JA, Christodoulou D, Krishna
MC, Pacelli R, Kim S, DeGraff W, Gamson J, Vodovotz Y, Russo A and
Mitchell JB: Nitric oxide and some nitric oxide donor compounds
enhance the cytotoxicity of cisplatin. Nitric Oxide. 1:88–94. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Huerta-Yepez S, Vega M, Escoto-Chavez SE,
Murdock B, Sakai T, Baritaki S and Bonavida B: Nitric oxide
sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of
the DR5 transcription repressor Yin Yang 1. Nitric Oxide. 20:39–52.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Huerta S, Baay-Guzman G, Gonzalez-Bonilla
CR, Livingston EH, Huerta-Yepez S and Bonavida B: In vitro and in
vivo sensitization of SW620 metastatic colon cancer cells to
CDDP-induced apoptosis by the nitric oxide donor DETANONOate:
Involvement of AIF. Nitric Oxide. 20:182–194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Bratasz A, Selvendiran K, Wasowicz T,
Bobko A, Khramtsov VV, Ignarro LJ and Kuppusamy P: NCX-4040, a
nitric oxide-releasing aspirin, sensitizes drug-resistant human
ovarian xenograft tumors to cisplatin by depletion of cellular
thiols. J Transl Med. 6:92008. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Safdar S, Payne CA, Tu NH and Taite LJ:
Targeted nitric oxide delivery preferentially induces glioma cell
chemosensitivity via altered p53 and O(6)-methylguanine-DNA
methyltransferase activity. Biotechnol Bioengering. 110:1211–1220.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Shami PJ, Saavedra JE, Wang LY, Bonifant
CL, Diwan BA, Singh SV, Gu Y, Fox SD, Buzard GS and Citro ML: JS-K,
a glutathione/glutathione S-transferase-activated nitric oxide
donor of the diazeniumdiolate class with potent antineoplastic
activity. Mol Cancer Ther. 2:409–417. 2003.PubMed/NCBI
|
|
151
|
Qiu M, Ke L, Zhang S, Zeng X, Fang Z and
Liu J: JS-K, a GST-activated nitric oxide donor prodrug, enhances
chemo-sensitivity in renal carcinoma cells and prevents cardiac
myocytes toxicity induced by Doxorubicin. Cancer Chemother
Pharmacol. 80:275–286. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Laschak M, Spindler KD, Schrader AJ,
Hessenauer A, Streicher W, Schrader M and Cronauer MV: JS-K, a
glutathione/glutathione S-transferase-activated nitric oxide
releasing prodrug inhibits androgen receptor and WNT-signaling in
prostate cancer cells. BMC Cancer. 12:1302012. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Qiu M, Chen L, Tan G, Ke L, Zhang S, Chen
H and Liu J: A reactive oxygen species activation mechanism
contributes to JS-K-induced apoptosis in human bladder cancer
cells. Sci Rep. 5:151042015. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Riganti C, Doublier S, Costamagna C,
Aldieri E, Pescarmona G, Ghigo D and Bosia A: Activation of nuclear
factor-kappa B pathway by simvastatin and RhoA silencing increases
doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol
Pharmacol. 74:476–484. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
De Boo S, Kopecka J, Brusa D, Gazzano E,
Matera L, Ghigo D, Bosia A and Riganti C: iNOS activity is
necessary for the cytotoxic and immunogenic effects of doxorubicin
in human colon cancer cells. Mol Cancer. 8:1082009. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Alimoradi H, Greish K, Barzegar-Fallah A,
Alshaibani L and Pittalà V: Nitric oxide-releasing nanoparticles
improve doxorubicin anticancer activity. Int J Nanomedicine.
13:7771–7787. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Sung YC, Jin PR, Chu LA, Hsu FF, Wang MR,
Chang CC, Chiou SJ, Qiu JT, Gao DY, Lin CC, et al: Delivery of
nitric oxide with a nanocarrier promotes tumour vessel
normalization and potentiates anti-cancer therapies. Nat
Nanotechnol. 14:1160–1169. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Pieretti JC, Pelegrino MT, Nascimento MHM,
Tortella GR, Rubilar O and Seabra AB: Small molecules for great
solutions: Can nitric oxide-releasing nanomaterials overcome drug
resistance in chemotherapy? Biochem Pharmacol. 176:1137402020.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Yasuda H, Nakayama K, Watanabe M, Suzuki
S, Fuji H, Okinaga S, Kanda A, Zayasu K, Sasaki T, Asada M, et al:
Nitroglycerin treatment may enhance chemosensitivity to docetaxel
and carboplatin in patients with lung adenocarcinoma. Clin Cancer
Res. 12:6748–6757. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Aalaei S, Mohammadzadeh M and Pazhang Y:
Synergistic induction of apoptosis in a cell model of human
leukemia K562 by nitroglycerine and valproic acid. EXCLI J.
18:619–630. 2019.PubMed/NCBI
|
|
161
|
Kaoud TS, Mohassab AM, Hassan HA, Yan C,
Van Ravenstein SX, Abdelhamid D, Dalby KN and Abdel-Aziz M:
NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth.
Eur J Med Chem. 186:1118852020. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Ishima Y, Kragh-Hansen U, Maruyama T and
Otagiri M: Poly-s-nitrosated albumin as a safe and effective
multifunctional antitumor agent: Characterization, biochemistry and
possible future therapeutic applications. Biomed Res Int.
2013:3538922013. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Ishima Y, Inoue A, Fang J, Kinoshita R,
Ikeda M, Watanabe H, Maeda H, Otagiri M and Maruyama T:
Poly-S-nitrosated human albumin enhances the antitumor and
antimetastasis effect of bevacizumab, partly by inhibiting
autophagy through the generation of nitric oxide. Cancer Sci.
106:194–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Li L, Whiteman M, Guan YY, Neo KL, Cheng
Y, Lee SW, Zhao Y, Baskar R, Tan CH and Moore PK: Characterization
of a novel, water-soluble hydrogen sulfide-releasing molecule
(GYY4137): New insights into the biology of hydrogen sulfide.
Circulation. 117:2351–2360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Lee ZW, Zhou J, Chen CS, Zhao Y, Tan CH,
Li L, Moore PK and Deng LW: The slow-releasing hydrogen sulfide
donor, GYY4137, exhibits novel anti-cancer effects in vitro and in
vivo. PLoS One. 6:e210772011. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Nalli AD, Bhattacharya S, Wang H, Kendig
DM, Grider JR and Murthy KS: Augmentation of cGMP/PKG pathway and
colonic motility by hydrogen sulfide. Am J Physiol Gastrointest
Liver Physiol. 313:G330–G341. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Liu B, Huang X, Li Y, Liao W, Li M, Liu Y,
He R, Feng D, Zhu R and Kurihara H: JS-K, a nitric oxide donor,
induces autophagy as a complementary mechanism inhibiting ovarian
cancer. BMC Cancer. 19:6452019. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Fonseca MD, Cunha FQ, Kashfi K and Cunha
TM: NOSH-aspirin (NBS-1120), a dual nitric oxide and hydrogen
sulfide-releasing hybrid, reduces inflammatory pain. Pharmacol Res
Perspect. 3:e001332015. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Rose P, Dymock BW and Moore PK: GYY4137, a
novel water-soluble, H2S-releasing molecule. Methods Enzymol.
554:143–167. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Aaltoma SH, Lipponen PK and Kosma VM:
Inducible nitric oxide synthase (iNOS) expression and its
prognostic value in prostate cancer. Anticancer Res. 21:3101–3106.
2001.PubMed/NCBI
|
|
171
|
Aaltomaa SH, Lipponen PK, Viitanen J,
Kankkunen JP, Ala-Opas MY and Kosma VM: The prognostic value of
inducible nitric oxide synthase in local prostate cancer. BJU Int.
86:234–239. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Bhowmick R and Girotti AW: Pro-survival
and pro-growth effects of stress-induced nitric oxide in a prostate
cancer photodynamic therapy model. Cancer Lett. 343:115–122. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Coulter JA, Page NL, Worthington J, Robson
T, Hirst DG and McCarthy HO: Transcriptional regulation of
inducible nitric oxide synthase gene therapy: Targeting early stage
and advanced prostate cancer. J Gene Med. 12:755–765. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Cronauer MV, Ince Y, Engers R, Rinnab L,
Weidemann W, Suschek CV, Burchardt M, Kleinert H, Wiedenmann J,
Sies H, et al: Nitric oxide-mediated inhibition of androgen
receptor activity: Possible implications for prostate cancer
progression. Oncogene. 26:1875–1884. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Erlandsson A, Carlsson J, Andersson SO,
Vyas C, Wikström P, Andrén O, Davidsson S and Rider JR: High
inducible nitric oxide synthase in prostate tumor epithelium is
associated with lethal prostate cancer. Scand J Urol. 52:129–133.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
McCarthy HO, Coulter JA, Worthington J,
Robson T and Hirst DG: Human osteocalcin: A strong promoter for
nitric oxide synthase gene therapy, with specificity for hormone
refractory prostate cancer. J Gene Med. 9:511–520. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Fahey JM and Girotti AW: Accelerated
migration and invasion of prostate cancer cells after a
photodynamic therapy-like challenge: Role of nitric oxide. Nitric
Oxide. 49:47–55. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
D'Este F, Della Pietra E, Badillo Pazmay
GV, Xodo LE and Rapozzi V: Role of nitric oxide in the response to
photooxidative stress in prostate cancer cells. Biochem Pharmacol.
182:1142052020. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Ryk C, de Verdier P, Montgomery E, Peter
Wiklund N, Wiklund F and Gronberg H: Polymorphisms in the
nitric-oxide synthase 2 gene and prostate cancer pathogenesis.
Redox Biol. 5:4192015. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Uotila P, Valve E, Martikainen P,
Nevalainen M, Nurmi M and Harkonen P: Increased expression of
cyclooxygenase-2 and nitric oxide synthase-2 in human prostate
cancer. Urol Res. 29:23–28. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Abdelmagid SA, Rickard JA, McDonald WJ,
Thomas LN and Too CK: CAT-1-mediated arginine uptake and regulation
of nitric oxide synthases for the survival of human breast cancer
cell lines. J Cell Biochem. 112:1084–1092. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Abdelmagid SA and Too CK: Prolactin and
estrogen up-regulate carboxypeptidase-d to promote nitric oxide
production and survival of mcf-7 breast cancer cells.
Endocrinology. 149:4821–4828. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Ambs S and Glynn SA: Candidate pathways
linking inducible nitric oxide synthase to a basal-like
transcription pattern and tumor progression in human breast cancer.
Cell Cycle. 10:619–624. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Alalami O and Martin JH: ZR-75-1 human
breast cancer cells: Expression of inducible nitric oxide synthase
and effect of tamoxifen and phorbol ester on nitric oxide
production. Cancer Lett. 123:99–105. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Basudhar D, Somasundaram V, de Oliveira
GA, Kesarwala A, Heinecke JL, Cheng RY, Glynn SA, Ambs S, Wink DA
and Ridnour LA: Nitric oxide synthase-2-derived nitric oxide drives
multiple pathways of breast cancer progression. Antioxid Redox
Signal. 26:1044–1058. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Bentrari F, Arnould L, Jackson AP, Jeannin
JF and Pance A: Progesterone enhances cytokine-stimulated nitric
oxide synthase II expression and cell death in human breast cancer
cells. Lab Invest. 85:624–632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Bing RJ, Miyataka M, Rich KA, Hanson N,
Wang X, Slosser HD and Shi SR: Nitric oxide, prostanoids,
cyclooxygenase, and angiogenesis in colon and breast cancer. Clin
Cancer Res. 7:3385–3392. 2001.PubMed/NCBI
|
|
188
|
Deepa M, Sureshkumar T, Satheeshkumar PK
and Priya S: Antioxidant rich Morus alba leaf extract induces
apoptosis in human colon and breast cancer cells by the
downregulation of nitric oxide produced by inducible nitric oxide
synthase. Nutr Cancer. 65:305–310. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Duenas-Gonzalez A, Isales CM, del Mar
Abad-Hernandez M, Gonzalez-Sarmiento R, Sangueza O and
Rodriguez-Commes J: Expression of inducible nitric oxide synthase
in breast cancer correlates with metastatic disease. Mod Pathol.
10:645–649. 1997.PubMed/NCBI
|
|
190
|
Evig CB, Kelley EE, Weydert CJ, Chu Y,
Buettner GR and Burns CP: Endogenous production and exogenous
exposure to nitric oxide augment doxorubicin cytotoxicity for
breast cancer cells but not cardiac myoblasts. Nitric Oxide.
10:119–129. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Flaherty RL, Intabli H, Falcinelli M,
Bucca G, Hesketh A, Patel BA, Allen MC, Smith CP and Flint MS:
Stress hormone-mediated acceleration of breast cancer metastasis is
halted by inhibition of nitric oxide synthase. Cancer letters.
459:59–71. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Garrido P, Shalaby A, Walsh EM, Keane N,
Webber M, Keane MM, Sullivan FJ, Kerin MJ, Callagy G, Ryan AE and
Glynn SA: Impact of inducible nitric oxide synthase (iNOS)
expression on triple negative breast cancer outcome and activation
of EGFR and ERK signaling pathways. Oncotarget. 8:80568–80588.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Hsu JT, Ying C and Chen CJ: Regulation of
inducible nitric oxide synthase by dietary phytoestrogen in MCF-7
human mammary cancer cells. Reprod Nutr Dev. 40:11–18. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Kanugula AK, Gollavilli PN, Vasamsetti SB,
Karnewar S, Gopoju R, Ummanni R and Kotamraju S: Statin-induced
inhibition of breast cancer proliferation and invasion involves
attenuation of iron transport: Intermediacy of nitric oxide and
antioxidant defence mechanisms. FEBS J. 281:3719–3738. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Kotamraju S, Williams CL and Kalyanaraman
B: Statin-induced breast cancer cell death: Role of inducible
nitric oxide and arginase-dependent pathways. Cancer Res.
67:7386–7394. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
López-Sánchez LM, Mena R, Guil-Luna S,
Mantrana A, Peñarando J, Toledano-Fonseca M, Conde F, De la
Haba-Rodríguez JR, Aranda E and Rodríguez-Ariza A: Nitric
oxide-targeted therapy inhibits stemness and increases the efficacy
of tamoxifen in estrogen receptor-positive breast cancer cells. Lab
Invest. 101:292–303. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Loibl S, Buck A, Strank C, von Minckwitz
G, Roller M, Sinn HP, Schini-Kerth V, Solbach C, Strebhardt K and
Kaufmann M: The role of early expression of inducible nitric oxide
synthase in human breast cancer. Eur J Cancer. 41:265–271. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Lahiri M and Martin JH: Reduced expression
of endothelial and inducible nitric oxide synthase in a multidrug
resistant variant of the MCF-7 human breast cancer cell line. Oncol
Rep. 12:1007–1011. 2004.PubMed/NCBI
|
|
199
|
Oktem G, Karabulut B, Selvi N, Sezgin C,
Sanli UA, Uslu R, Yurtseven ME and Omay SB: Differential effects of
doxorubicin and docetaxel on nitric oxide production and inducible
nitric oxide synthase expression in MCF-7 human breast cancer
cells. Oncol Res. 14:381–386. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Martin JH, Alalami O and van den Berg HW:
Reduced expression of endothelial and inducible nitric oxide
synthase in a human breast cancer cell line which has acquired
estrogen independence. Cancer Lett. 144:65–74. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Nafea H, Youness RA, Abou-Aisha K and Gad
MZ: LncRNA HEIH/miR-939-5p interplay modulates triple-negative
breast cancer progression through NOS2-induced nitric oxide
production. J Cell Physiol. 236:5362–5372. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Oktem G, Bilir A, Selvi N, Yurtseven ME,
Vatansever S, Ates U, Uysal A and Omay SB: Chemotherapy influences
inducible nitric oxide synthase (iNOS) and endothelial nitric oxide
synthase (eNOS) activity on 3D breast cancer cell line. Oncol Res.
16:195–203. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Zeybek ND, Inan S, Ekerbicer N, Vatansever
HS, Karakaya J and Muftuoglu SF: The effects of Gemcitabine and
Vinorelbine on inducible nitric oxide synthase (iNOS) and
endothelial nitric oxide synthase (eNOS) distribution of MCF-7
breast cancer cells. Acta Histochem. 113:62–67. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Walsh EM, Keane MM, Wink DA, Callagy G and
Glynn SA: Review of triple negative breast cancer and the impact of
inducible nitric oxide synthase on tumor biology and patient
outcomes. Crit Rev Oncog. 21:333–351. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Wink DA, Ridnour LA, Cheng R, Switzer CW,
Glynn S and Ambs S: The oncogenic properties of the redox
inflammatory protein inducible nitric oxide synthase in ER(−)
breast cancer. Redox Biol. 5:4132015. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Tschugguel W, Schneeberger C, Unfried G,
Czerwenka K, Weninger W, Mildner M, Gruber DM, Sator MO, Waldhör T
and Huber JC: Expression of inducible nitric oxide synthase in
human breast cancer depends on tumor grade. Breast Cancer Res
Treat. 56:145–151. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Abadi AT and Kusters JG: Association of
inducible nitric oxide synthetase genotype and Helicobacter pylori
infection gastric cancer risk may be due to faulty primer design.
World J Gastroenterol. 19:429–430. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Chen CN, Hsieh FJ, Cheng YM, Chang KJ and
Lee PH: Expression of inducible nitric oxide synthase and
cyclooxygenase-2 in angiogenesis and clinical outcome of human
gastric cancer. J Surg Oncol. 94:226–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Doi C, Noguchi Y, Marat D, Saito A,
Fukuzawa K, Yoshikawa T, Tsuburaya A and Ito T: Expression of
nitric oxide synthase in gastric cancer. Cancer Lett. 144:161–167.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Goto T, Haruma K, Kitadai Y, Ito M,
Yoshihara M, Sumii K, Hayakawa N and Kajiyama G: Enhanced
expression of inducible nitric oxide synthase and nitrotyrosine in
gastric mucosa of gastric cancer patients. Clin Cancer Res.
5:1411–1415. 1999.PubMed/NCBI
|
|
211
|
Goto Y, Ando T, Naito M, Goto H and
Hamajima N: Inducible nitric oxide synthase polymorphism is
associated with the increased risk of differentiated gastric cancer
in a Japanese population. World J Gastroenterol. 12:6361–6365.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Hirst D and Robson T: Nitric oxide in
cancer therapeutics: Interaction with cytotoxic chemotherapy. Curr
Pharm Des. 16:411–420. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Hirahashi M, Koga Y, Kumagai R, Aishima S,
Taguchi K and Oda Y: Induced nitric oxide synthetase and
peroxiredoxin expression in intramucosal poorly differentiated
gastric cancer of young patients. Pathol Int. 64:155–163. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Huang FY, Chan AO, Rashid A, Wong DK, Cho
CH and Yuen MF: Helicobacter pylori induces promoter methylation of
E-cadherin via interleukin-1β activation of nitric oxide production
in gastric cancer cells. Cancer. 118:4969–4980. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Ikeguchi M, Ueta T and Kaibara N:
Expression of inducible nitric oxide synthase during
cisplatin-based chemotherapy for gastric cancer. In Vivo.
16:185–190. 2002.PubMed/NCBI
|
|
216
|
Jun Y, Fei G, Ebert MP and Malfertheiner
P: Expression of inducible nitric oxide synthase in human gastric
cancer. World J Gastroenterol. 5:430–431. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Jung ID, Lee JS, Yun SY, Park CG, Han JW,
Lee HW and Lee HY: Doxorubicin inhibits the production of nitric
oxide by colorectal cancer cells. Arch Pharm Res. 25:691–696. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Rafiei A, Hosseini V, Janbabai G, Fazli B,
Ajami A, Hosseini-Khah Z, Gilbreath J and Merrell DS: Inducible
nitric oxide synthetase genotype and helicobacter pylori infection
affect gastric cancer risk. World J Gastroenterol. 18:4917–4924.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Rajnakova A, Moochhala S, Goh PM and Ngoi
S: Expression of nitric oxide synthase, cyclooxygenase, and p53 in
different stages of human gastric cancer. Cancer Lett. 172:177–185.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Zhang W, He XJ, Ma YY, Wang HJ, Xia YJ,
Zhao ZS, Ye ZY and Tao HQ: Inducible nitric oxide synthase
expression correlates with angiogenesis, lymphangiogenesis, and
poor prognosis in gastric cancer patients. Hum Pathol.
42:1275–1282. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Sawa T, Mounawar M, Tatemichi M, Gilibert
I, Katoh T and Ohshima H: Increased risk of gastric cancer in
Japanese subjects is associated with microsatellite polymorphisms
in the heme oxygenase-1 and the inducible nitric oxide synthase
gene promoters. Cancer Lett. 269:78–84. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Shen J, Wang RT, Wang LW, Xu YC and Wang
XR: A novel genetic polymorphism of inducible nitric oxide synthase
is associated with an increased risk of gastric cancer. World J
Gastroenterol. 10:3278–3283. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Son HJ, Kim YH, Park DI, Kim JJ, Rhee PL,
Paik SW, Choi KW, Song SY and Rhee JC: Interaction between
cyclooxygenase-2 and inducible nitric oxide synthase in gastric
cancer. J Clin Gastroenterol. 33:383–388. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Song ZY, Wen SQ, Peng JP, Huang X and Qian
KD: Significance of vascular endothelial growth factor expression
and its correlation with inducible nitric oxide synthase in gastric
cancer. World J Gastroenterol. 10:1250–1255. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Ambs S, Merriam WG, Bennett WP,
Felley-Bosco E, Ogunfusika MO, Oser SM, Klein S, Shields PG,
Billiar TR and Harris CC: Frequent nitric oxide synthase-2
expression in human colon adenomas: Implication for tumor
angiogenesis and colon cancer progression. Cancer Res. 58:334–341.
1998.PubMed/NCBI
|
|
226
|
Bocca C, Bozzo F, Bassignana A and
Miglietta A: Antiproliferative effect of a novel nitro-oxy
derivative of celecoxib in human colon cancer cells: Role of COX-2
and nitric oxide. Anticancer Res. 30:2659–2666. 2010.PubMed/NCBI
|
|
227
|
Dabrowska M, Uram L, Zielinski Z, Rode W
and Sikora E: Oxidative stress and inhibition of nitric oxide
generation underlie methotrexate-induced senescence in human colon
cancer cells. Mech Ageing Dev. 170:22–29. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Narayanan BA, Narayanan NK, Desai D,
Pittman B and Reddy BS: Effects of a combination of docosahexaenoic
acid and 1,4-phenylene bis(methylene) selenocyanate on
cyclooxygenase 2, inducible nitric oxide synthase and beta-catenin
pathways in colon cancer cells. Carcinogenesis. 25:2443–2449. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Narayanan BA, Narayanan NK, Simi B and
Reddy BS: Modulation of inducible nitric oxide synthase and related
proinflammatory genes by the omega-3 fatty acid docosahexaenoic
acid in human colon cancer cells. Cancer Res. 63:972–979.
2003.PubMed/NCBI
|
|
230
|
Kwak JY, Han MK, Choi KS, Park IH, Park
SY, Sohn MH, Kim UH, McGregor JR, Samlowski WE and Yim CY:
Cytokines secreted by lymphokine-activated killer cells induce
endogenous nitric oxide synthesis and apoptosis in DLD-1 colon
cancer cells. Cell Immunol. 203:84–94. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Kapral M, Wawszczyk J, Sosnicki S and
Weglarz L: Down-regulation of inducible nitric oxide synthase
expression by inositol hexaphosphate in human colon cancer cells.
Acta Pol Pharm. 72:705–711. 2015.PubMed/NCBI
|
|
232
|
Puglisi MA, Cenciarelli C, Tesori V,
Cappellari M, Martini M, Di Francesco AM, Giorda E, Carsetti R,
Ricci-Vitiani L and Gasbarrini A: High nitric oxide production,
secondary to inducible nitric oxide synthase expression, is
essential for regulation of the tumour-initiating properties of
colon cancer stem cells. J Pathol. 236:479–490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Williams JL, Nath N, Chen J, Hundley TR,
Gao J, Kopelovich L, Kashfi K and Rigas B: Growth inhibition of
human colon cancer cells by nitric oxide (NO)-donating aspirin is
associated with cyclooxygenase-2 induction and beta-catenin/T-cell
factor signaling, nuclear factor-kappaB, and NO synthase 2
inhibition: Implications for chemoprevention. Cancer Res.
63:7613–7618. 2003.PubMed/NCBI
|
|
234
|
Tong X, Zheng S, Jin J, Zhu L, Lou Y and
Yao H: Triptolide inhibits cyclooxygenase-2 and inducible nitric
oxide synthase expression in human colon cancer and leukemia cells.
Acta Biochim Biophys Sin (Shanghai). 39:89–95. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Sasahara Y, Mutoh M, Takahashi M, Fukuda
K, Tanaka N, Sugimura T and Wakabayashi K: Suppression of
promoter-dependent transcriptional activity of inducible nitric
oxide synthase by sodium butyrate in colon cancer cells. Cancer
Lett. 177:155–161. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Shen X, Chen J, Qiu R, Fan X and Xin Y:
Effect of camptothecin on inducible nitric oxide synthase
expression in the colon cancer SW480 cell line. Oncol Lett.
10:3157–3160. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Spiegel A, Hundley TR, Chen J, Ouyang N,
Liu X, Go MF, Tsioulias GJ, Kashfi K and Rigas B: NO-donating
aspirin inhibits both the expression and catalytic activity of
inducible nitric oxide synthase in HT-29 human colon cancer cells.
Biochem Pharmacol. 70:993–1000. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Eijan AM, Piccardo I, Riveros MD, Sandes
EO, Porcella H, Jasnis MA, Sacerdote De Lustig E, Malagrino H,
Pasik L and Casabé AR: Nitric oxide in patients with transitional
bladder cancer. J Surg Oncol. 81:203–208. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
239
|
Hosseini A, Koskela LR, Ehren I,
Aguilar-Santelises M, Sirsjo A and Wiklund NP: Enhanced formation
of nitric oxide in bladder carcinoma in situ and in BCG treated
bladder cancer. Nitric Oxide. 15:337–343. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Klotz T, Bloch W, Jacobs G, Niggemann S,
Engelmann U and Addicks K: Immunolocalization of inducible and
constitutive nitric oxide synthases in human bladder cancer.
Urology. 54:416–419. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
241
|
Koskela LR, Poljakovic M, Ehren I, Wiklund
NP and de Verdier PJ: Localization and expression of inducible
nitric oxide synthase in patients after BCG treatment for bladder
cancer. Nitric Oxide. 27:185–191. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
242
|
Langle YV, Balarino NP, Belgorosky D,
Cresta Morgado PD, Sandes EO, Marino L, Bilbao ER, Zambrano M,
Lodillinsky C and Eiján AM: Effect of nitric oxide inhibition in
Bacillus Calmette-Guerin bladder cancer treatment. Nitric Oxide.
98:50–59. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
243
|
Lin Z, Chen S, Ye C and Zhu S: Nitric
oxide synthase expression in human bladder cancer and its relation
to angiogenesis. Urol Res. 31:232–235. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
244
|
Ryk C, Steineck G, Wiklund NP, Nyberg T
and de Verdier PJ: The (CCTTT)n microsatellite polymorphism in the
nitric oxide synthase 2 gene may influence bladder cancer
pathogenesis. J Urol. 184:2150–2157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
245
|
Ryk C, Wiklund NP, Nyberg T and De Verdier
PJ: Ser608Leu polymorphisms in the nitric oxide synthase-2 gene may
influence urinary bladder cancer pathogenesis. Scand J Urol
Nephrol. 45:319–325. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
246
|
Wolf H, Haeckel C and Roessner A:
Inducible nitric oxide synthase expression in human urinary bladder
cancer. Virchows Arch. 437:662–666. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
247
|
Sandes EO, Faletti AG, Riveros MD, Vidal
Mdel C, Gimenez L, Casabé AR and Eiján AM: Expression of inducible
nitric oxide synthase in tumoral and non-tumoral epithelia from
bladder cancer patients. Nitric Oxide. 12:39–45. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
248
|
Sandes EO, Lodillinsky C, Langle Y,
Belgorosky D, Marino L, Gimenez L, Casabé AR and Eiján AM:
Inducible nitric oxide synthase and PPARγ are involved in bladder
cancer progression. J Urol. 188:967–973. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
249
|
Ambs S and Harris CC: RESPONSE: Re:
Relationship between p53 mutations and inducible nitric oxide
synthase expression in human colorectal cancer. J Natl Cancer Inst.
91:1510–1511. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
250
|
Chung P, Cook T, Liu K, Vodovotz Y, Zamora
R, Finkelstein S, Billiar T and Blumberg D: Overexpression of the
human inducible nitric oxide synthase gene enhances
radiation-induced apoptosis in colorectal cancer cells via a
caspase-dependent mechanism. Nitric Oxide. 8:119–126. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
251
|
Cianchi F, Cortesini C, Fantappie O,
Messerini L, Sardi I, Lasagna N, Perna F, Fabbroni V, Di Felice A,
Perigli G, et al: Cyclooxygenase-2 activation mediates the
proangiogenic effect of nitric oxide in colorectal cancer. Clin
Cancer Res. 10:2694–2704. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
252
|
Cianchi F, Cortesini C, Fantappie O,
Messerini L, Schiavone N, Vannacci A, Nistri S, Sardi I, Baroni G,
Marzocca C, et al: Inducible nitric oxide synthase expression in
human colorectal cancer: Correlation with tumor angiogenesis. Am J
Pathol. 162:793–801. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
253
|
Fransen K, Elander N and Soderkvist P:
Nitric oxide synthase 2 (NOS2) promoter polymorphisms in colorectal
cancer. Cancer Lett. 225:99–103. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
254
|
Gallo O, Sardi I, Masini M and Franchi A:
Re: Relationship between p53 mutations and inducible nitric oxide
synthase expression in human colorectal cancer. J Natl Cancer Inst.
91:1509–1511. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
255
|
Ropponen KM, Kellokoski JK, Lipponen PK,
Eskelinen MJ, Alanne L, Alhava EM and Kosma VM: Expression of
inducible nitric oxide synthase in colorectal cancer and its
association with prognosis. Scand J Gastroenterol. 35:1204–1211.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
256
|
Zafirellis K, Zachaki A, Agrogiannis G and
Gravani K: Inducible nitric oxide synthase expression and its
prognostic significance in colorectal cancer. APMIS. 118:115–124.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
257
|
Wang Z, Cook T, Alber S, Liu K, Kovesdi I,
Watkins SK, Vodovotz Y, Billiar TR and Blumberg D: Adenoviral gene
transfer of the human inducible nitric oxide synthase gene enhances
the radiation response of human colorectal cancer associated with
alterations in tumor vascularity. Cancer Res. 64:1386–1395. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
258
|
Delarue FL, Taylor BS and Sebti SM: Ras
and RhoA suppress whereas RhoB enhances cytokine-induced
transcription of nitric oxide synthase-2 in human normal liver
AKN-1 cells and lung cancer A-549 cells. Oncogene. 20:6531–6537.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
259
|
Hu C, Li G and Wu E: A study on the
activity of nitric oxide in alveolar macrophages from patients with
lung cancer. Hunan Yi Ke Da Xue Xue Bao. 23:157–160. 1998.(In
Chinese). PubMed/NCBI
|
|
260
|
Li Y, Ma C, Shi X, Wen Z, Li D, Sun M and
Ding H: Effect of nitric oxide synthase on multiple drug resistance
is related to Wnt signaling in non-small cell lung cancer. Oncol
Rep. 32:1703–1708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
261
|
Liu CY, Wang CH, Chen TC, Lin HC, Yu CT
and Kuo HP: Increased level of exhaled nitric oxide and
up-regulation of inducible nitric oxide synthase in patients with
primary lung cancer. Br J Cancer. 78:534–541. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
262
|
Liu CY, Wang YM, Wang CL, Feng PH, Ko HW,
Liu YH, Wu YC, Chu Y, Chung FT, Kuo CH, et al: Population
alterations of L-arginase- and inducible nitric oxide
synthase-expressed CD11b+/CD14-/CD15+/CD33+ myeloid-derived
suppressor cells and CD8+ T lymphocytes in patients with
advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol.
136:35–45. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
263
|
Zhang J, Li B, Ding X, Sun M, Li H, Yang
M, Zhou C, Yu H, Liu H and Yu G: Genetic variants in inducible
nitric oxide synthase gene are associated with the risk of
radiation-induced lung injury in lung cancer patients receiving
definitive thoracic radiation. Radiother Oncol. 111:194–198. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
264
|
Ye S, Yang W, Wang Y, Ou W, Ma Q, Yu C,
Ren J, Zhong G, Shi H, Yuan Z, et al: Cationic liposome-mediated
nitric oxide synthase gene therapy enhances the antitumor effects
of cisplatin in lung cancer. Int J Mol Med. 31:33–42. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
265
|
Sim SH, Ahn YO, Yoon J, Kim TM, Lee SH,
Kim DW and Heo DS: Influence of chemotherapy on nitric oxide
synthase, indole-amine-2,3-dioxygenase and CD124 expression in
granulocytes and monocytes of non-small cell lung cancer. Cancer
Sci. 103:155–160. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
266
|
Franco L, Doria D, Bertazzoni E, Benini A
and Bassi C: Increased expression of inducible nitric oxide
synthase and cyclooxygenase-2 in pancreatic cancer. Prostaglandins
Other Lipid Mediat. 73:51–58. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
267
|
Kong G, Kim E, Kim W, Lee YW, Lee JK, Paik
SW, Rhee JC, Choi KW and Lee KT: Inducible nitric oxide synthase
(iNOS) immunoreactivity and its relationship to cell proliferation,
apoptosis, angiogenesis, clinicopathologic characteristics, and
patient survival in pancreatic cancer. Int J Pancreatol.
29:133–140. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
268
|
Kong G, Kim EK, Kim WS, Lee KT, Lee YW,
Lee JK, Paik SW and Rhee JC: Role of cyclooxygenase-2 and inducible
nitric oxide synthase in pancreatic cancer. J Gastroenterol
Hepatol. 17:914–921. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
269
|
Wang J, He P, Gaida M, Yang S, Schetter
AJ, Gaedcke J, Ghadimi BM, Ried T, Yfantis H, Lee D, et al:
Inducible nitric oxide synthase enhances disease aggressiveness in
pancreatic cancer. Oncotarget. 7:52993–53004. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
270
|
Vickers SM, MacMillan-Crow LA, Green M,
Ellis C and Thompson JA: Association of increased immunostaining
for inducible nitric oxide synthase and nitrotyrosine with
fibroblast growth factor transformation in pancreatic cancer. Arch
Surg. 134:245–251. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
271
|
Takahashi M, Kitahashi T, Ishigamori R,
Mutoh M, Komiya M, Sato H, Kamanaka Y, Naka M, Maruyama T, Sugimura
T and Wakabayashi K: Increased expression of inducible nitric oxide
synthase (iNOS) in N-nitrosobis(2-oxopropyl)amine-induced hamster
pancreatic carcinogenesis and prevention of cancer development by
ONO-1714, an iNOS inhibitor. Carcinogenesis. 29:1608–1613. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
272
|
Chen HH, Su WC, Chou CY, Guo HR, Ho SY,
Que J and Lee WY: Increased expression of nitric oxide synthase and
cyclooxygenase-2 is associated with poor survival in cervical
cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys.
63:1093–1100. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
273
|
Dong J, Cheng M and Sun H: Function of
inducible nitric oxide synthase in the regulation of cervical
cancer cell proliferation and the expression of vascular
endothelial growth factor. Mol Med Rep. 9:583–589. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
274
|
Jiang N, Tian Z, Tang J, Ou R and Xu Y:
Granulocyte macrophage-colony stimulating factor (GM-CSF)
downregulates the expression of protumor factors cyclooxygenase-2
and inducible nitric oxide synthase in a GM-CSF
receptor-independent manner in cervical cancer cells. Mediators
Inflamm. 2015:6016042015. View Article : Google Scholar : PubMed/NCBI
|
|
275
|
Lee TS, Jeon YT, Kim JW, Park NH, Kang SB,
Lee HP and Song YS: Lack of association of the cyclooxygenase-2 and
inducible nitric oxide synthase gene polymorphism with risk of
cervical cancer in Korean population. Ann N Y Acad Sci.
1095:134–142. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
276
|
Ryu YK, Lee JW and Moon EY: Thymosin
beta-4, actin-sequestering protein regulates vascular endothelial
growth factor expression via hypoxia-inducible nitric oxide
production in HeLa cervical cancer cells. Biomol Ther (Seoul).
23:19–25. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
277
|
Sowjanya AP, Rao M, Vedantham H, Kalpana
B, Poli UR, Marks MA and Sujatha M: Correlation of plasma
nitrite/nitrate levels and inducible nitric oxide gene expression
among women with cervical abnormalities and cancer. Nitric Oxide.
52:21–28. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
278
|
Li L, Zhu L, Hao B, Gao W, Wang Q, Li K,
Wang M, Huang M, Liu Z, Yang Q, et al: iNOS-derived nitric oxide
promotes glycolysis by inducing pyruvate kinase M2 nuclear
translocation in ovarian cancer. Oncotarget. 8:33047–33063. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
279
|
Malone JM, Saed GM, Diamond MP, Sokol RJ
and Munkarah AR: The effects of the inhibition of inducible nitric
oxide synthase on angiogenesis of epithelial ovarian cancer. Am J
Obstet Gynecol. 194:1110–1118. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
280
|
Martins Filho A, Jammal MP, Cobo Ede C,
Silveira TP, Adad SJ, Murta EF and Nomelini RS: Correlation of
cytokines and inducible nitric oxide synthase expression with
prognostic factors in ovarian cancer. Immunol Lett. 158:195–199.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
281
|
Raspollini MR, Amunni G, Villanucci A,
Boddi V, Baroni G, Taddei A and Taddei GL: Expression of inducible
nitric oxide synthase and cyclooxygenase-2 in ovarian cancer:
Correlation with clinical outcome. Gynecol Oncol. 92:806–812. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
282
|
Zhao L, Yu C, Zhou S, Lau WB, Lau B, Luo
Z, Lin Q, Yang H, Xuan Y, Yi T, et al: Epigenetic repression of
PDZ-LIM domain-containing protein 2 promotes ovarian cancer via
NOS2-derived nitric oxide signaling. Oncotarget. 7:1408–1420. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
283
|
Xu L, Xie K and Fidler IJ: Therapy of
human ovarian cancer by transfection with the murine interferon
beta gene: Role of macrophage-inducible nitric oxide synthase. Hum
Gene Ther. 9:2699–2708. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
284
|
Trinh B, Ko SY, Haria D, Barengo N and
Naora H: The homeoprotein DLX4 controls inducible nitric oxide
synthase-mediated angiogenesis in ovarian cancer. Mol Cancer.
14:972015. View Article : Google Scholar : PubMed/NCBI
|
|
285
|
Sanhueza C, Araos J, Naranjo L, Barros E,
Toledo L, Subiabre M, Toledo F, Gutiérrez J, Chiarello DI, Pardo F,
et al: Are NHE1 and inducible nitric oxide synthase involved in
human ovarian cancer? Pharmacol Res. 105:183–185. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
286
|
Jayasurya A, Dheen ST, Yap WM, Tan NG, Ng
YK and Bay BH: Inducible nitric oxide synthase and bcl-2 expression
in nasopharyngeal cancer: Correlation with outcome of patients
after radiotherapy. Int J Radiat Oncol Biol Phys. 56:837–845. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
287
|
Lukes P, Pacova H, Kucera T, Vesely D,
Martinek J and Astl J: Expression of endothelial and inducible
nitric oxide synthase and caspase-3 in tonsillar cancer, chronic
tonsillitis and healthy tonsils. Folia Biol (Praha). 54:141–145.
2008.PubMed/NCBI
|
|
288
|
Soler MN, Bobe P, Benihoud K, Lemaire G,
Roos BA and Lausson S: Gene therapy of rat medullary thyroid cancer
by naked nitric oxide synthase II DNA injection. J Gene Med.
2:344–352. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
289
|
Rafa H, Benkhelifa S, AitYounes S, Saoula
H, Belhadef S, Belkhelfa M, Boukercha A, Toumi R, Soufli I, Moralès
O, et al: All-trans retinoic acid modulates TLR4/NF-κB signaling
pathway targeting TNF-α and nitric oxide synthase 2 expression in
colonic mucosa during ulcerative colitis and colitis associated
cancer. Mediators Inflamm. 2017:73532522017. View Article : Google Scholar : PubMed/NCBI
|
|
290
|
Amasyali AS, Kucukgergin C, Erdem S, Sanli
O, Seckin S and Nane I: Nitric oxide synthase (eNOS4a/b) gene
polymorphism is associated with tumor recurrence and progression in
superficial bladder cancer cases. J Urol. 188:2398–2403. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
291
|
Polat F, Diler SB, Azazi İ and Öden A:
T-786C, G894T, and intron 4 VNTR (4a/b) polymorphisms of the
endothelial nitric oxide synthase gene in bladder cancer cases.
Asian Pac J Cancer Prev. 16:2199–2202. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
292
|
Ryk C, Wiklund NP, Nyberg T and de Verdier
PJ: Polymorphisms in nitric-oxide synthase 3 may influence the risk
of urinary-bladder cancer. Nitric Oxide. 25:338–343. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
293
|
Abedinzadeh M, Dastgheib SA, Maleki H,
Heiranizadeh N, Zare M, Jafari-Nedooshan J, Kargar S and
Neamatzadeh H: Association of endothelial nitric oxide synthase
gene polymorphisms with susceptibility to prostate cancer: A
comprehensive systematic review and meta-analysis. Urol J.
17:329–337. 2020.PubMed/NCBI
|
|
294
|
Branković A, Brajušković G, Nikolić Z,
Vukotić V, Cerović S, Savić-Pavićević D and Romac S: Endothelial
nitric oxide synthase gene polymorphisms and prostate cancer risk
in Serbian population. Int J Exp Pathol. 94:355–361. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
295
|
Diler SB and Oden A: The T-786C, G894T,
and intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric
oxide synthase gene in prostate cancer cases. Genetika. 52:249–254.
2016.PubMed/NCBI
|
|
296
|
Fu Q, Liu X, Liu Y, Yang J, Lv G and Dong
S: MicroRNA-335 and −543 suppress bone metastasis in prostate
cancer via targeting endothelial nitric oxide synthase. Int J Mol
Med. 36:1417–1425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
297
|
Medeiros R, Morais A, Vasconcelos A, Costa
S, Carrilho S, Oliveira J and Lopes C: Endothelial nitric oxide
synthase gene polymorphisms and the shedding of circulating tumour
cells in the blood of prostate cancer patients. Cancer Lett.
189:85–90. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
298
|
Medeiros R, Morais A, Vasconcelos A, Costa
S, Pinto D, Oliveira J and Lopes C: Endothelial nitric oxide
synthase gene polymorphisms and genetic susceptibility to prostate
cancer. Eur J Cancer Prev. 11:343–350. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
299
|
Medeiros RM, Morais A, Vasconcelos A,
Costa S, Pinto D, Oliveira J, Ferreira P and Lopes C: Outcome in
prostate cancer: Association with endothelial nitric oxide synthase
Glu-Asp298 polymorphism at exon 7. Clin Cancer Res. 8:3433–3437.
2002.PubMed/NCBI
|
|
300
|
Nikolic ZZ, Pavicevic D, Romac SP and
Brajuskovic GN: Genetic variants within endothelial nitric oxide
synthase gene and prostate cancer: A meta-analysis. Clin Transl
Sci. 8:23–31. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
301
|
Marangoni K, Neves AF, Cardoso AM, Santos
WK, Faria PC and Goulart LR: The endothelial nitric oxide synthase
Glu-298-Asp polymorphism and its mRNA expression in the peripheral
blood of patients with prostate cancer and benign prostatic
hyperplasia. Cancer Detect Prev. 30:7–13. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
302
|
Polytarchou C, Hatziapostolou M, Poimenidi
E, Mikelis C, Papadopoulou A, Parthymou A and Papadimitriou E:
Nitric oxide stimulates migration of human endothelial and prostate
cancer cells through up-regulation of pleiotrophin expression and
its receptor protein tyrosine phosphatase beta/zeta. Int J Cancer.
124:1785–1793. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
303
|
Re A, Aiello A, Nanni S, Grasselli A,
Benvenuti V, Pantisano V, Strigari L, Colussi C, Ciccone S,
Mazzetti AP, et al: Silencing of GSTP1, a prostate cancer
prognostic gene, by the estrogen receptor-β and endothelial nitric
oxide synthase complex. Mol Endocrinol. 25:2003–2016. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
304
|
Re A, Colussi C, Nanni S, Aiello A, Bacci
L, Grassi C, Pontecorvi A and Farsetti A: Nucleoporin 153 regulates
estrogen-dependent nuclear translocation of endothelial nitric
oxide synthase and estrogen receptor beta in prostate cancer.
Oncotarget. 9:27985–27997. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
305
|
Ziaei SA, Samzadeh M, Jamaldini SH,
Afshari M, Haghdoost AA and Hasanzad M: Endothelial nitric oxide
synthase Glu298Asp polymorphism as a risk factor for prostate
cancer. Int J Biol Markers. 28:43–48. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
306
|
Zhao C, Yan W, Zu X, Chen M, Liu L, Zhao
S, Liu H, Hu X, Luo R, Xia Y and Qi L: Association between
endothelial nitric oxide synthase 894G>T polymorphism and
prostate cancer risk: A meta-analysis of literature studies. Tumour
Biol. 35:11727–11733. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
307
|
Yu S, Jia L, Zhang Y, Wu D, Xu Z, Ng CF,
To KK, Huang Y and Chan FL: Increased expression of activated
endothelial nitric oxide synthase contributes to antiandrogen
resistance in prostate cancer cells by suppressing androgen
receptor transactivation. Cancer Lett. 328:83–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
308
|
Wu JH, Yang K, Ma HS and Xu Y: Association
of endothelia nitric oxide synthase gene rs1799983 polymorphism
with susceptibility to prostate cancer: A meta-analysis. Tumour
Biol. 35:7057–7062. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
309
|
Safarinejad MR and Safarinejad S, Shafiei
N and Safarinejad S: Effects of the T-786C, G894T, and Intron 4
VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase
gene on the risk of prostate cancer. Urol Oncol. 31:1132–1140.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
310
|
Sanli O, Kucukgergin C, Gokpinar M, Tefik
T, Nane I and Seckin S: Despite the lack of association between
different genotypes and the presence of prostate cancer,
endothelial nitric oxide synthase a/b (eNOS4a/b) polymorphism may
be associated with advanced clinical stage and bone metastasis.
Urol Oncol. 29:183–188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
311
|
Bayraktutan Z, Kiziltunc A, Bakan E and
Alp HH: Determination of endothelial nitric oxide synthase gene
polymorphism and plasma asymmetric dimethyl arginine concentrations
in patients with lung cancer. Eurasian J Med. 52:185–190. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
312
|
Cheon KT, Choi KH, Lee HB, Park SK, Rhee
YK and Lee YC: Gene polymorphisms of endothelial nitric oxide
synthase and angiotensin-converting enzyme in patients with lung
cancer. Lung. 178:351–360. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
313
|
Fujita S, Masago K, Hatachi Y, Fukuhara A,
Hata A, Kaji R, Kim YH, Mio T, Mishima M and Katakami N: Genetic
polymorphisms in the endothelial nitric oxide synthase gene
correlate with overall survival in advanced non-small-cell lung
cancer patients treated with platinum-based doublet chemotherapy.
BMC Med Genet. 11:1672010. View Article : Google Scholar : PubMed/NCBI
|
|
314
|
Kocer C, Benlier N, Balci SO, Pehlivan S,
Sanli M and Nacak M: The role of endothelial nitric oxide synthase
gene polymorphisms in patients with lung cancer. Clin Respir J.
14:948–955. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
315
|
Peddireddy V, Badabagni SP, Gundimeda SD
and Mundluru HP: Association of eNOS and ACE gene polymorphisms and
plasma nitric oxide with risk of non-small cell lung cancer in
South India. Clin Respir J. 12:207–217. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
316
|
Chen CH, Wu SH, Tseng YM, Hou MF, Tsai LY
and Tsai SM: Distinct role of endothelial nitric oxide synthase
gene polymorphisms from menopausal status in the patients with
sporadic breast cancer in Taiwan. Nitric Oxide. 72:1–6. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
317
|
Crucitta S, Restante G, Del Re M,
Bertolini I, Bona E, Rofi E, Fontanelli L, Gianfilippo G, Fogli S,
Stasi I, et al: Endothelial nitric oxide synthase c.-813C>T
predicts for proteinuria in metastatic breast cancer patients
treated with bevacizumab-based chemotherapy. Cancer Chemother
Pharmacol. 84:1219–1227. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
318
|
Basaran G, Turhal NS, Cabuk D, Yurt N,
Yurtseven G, Gumus M, Teomete M, Dane F and Yumuk PF: Weight gain
after adjuvant chemotherapy in patients with early breast cancer in
Istanbul Turkey. Med Oncol. 28:409–415. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
319
|
Hao Y, Montiel R and Huang Y: Endothelial
nitric oxide synthase (eNOS) 894 G>T polymorphism is associated
with breast cancer risk: A meta-analysis. Breast Cancer Res Treat.
124:809–813. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
320
|
Hefler LA, Grimm C, Lantzsch T, Lampe D,
Koelbl H, Lebrecht A, Heinze G, Tempfer C, Reinthaller A and
Zeillinger R: Polymorphisms of the endothelial nitric oxide
synthase gene in breast cancer. Breast Cancer Res Treat.
98:151–155. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
321
|
Kafousi M, Vrekoussis T, Tsentelierou E,
Pavlakis K, Navrozoglou I, Dousias V, Sanidas E, Tsiftsis D,
Georgoulias V and Stathopoulos EN: Immunohistochemical study of the
angiogenetic network of VEGF, HIF1α, VEGFR-2 and endothelial nitric
oxide synthase (eNOS) in human breast cancer. Pathol Oncol Res.
18:33–41. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
322
|
Loibl S, Bratengeier J, Farines V, von
Minckwitz G, Spänkuch B, Schini-Kerth V, Nepveu F, Strebhardt K and
Kaufmann M: Investigations on the inducible and endothelial nitric
oxide synthases in human breast cancer cell line MCF-7-estrogen has
an influence on e-NOS, but not on i-NOS. Pathol Res Pract. 202:1–7.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
323
|
Loibl S, Strank C, von Minckwitz G, Sinn
HP, Buck A, Solbach C, Strebhardt K and Kaufmann M:
Immunohistochemical evaluation of endothelial nitric oxide synthase
expression in primary breast cancer. Breast. 14:230–235. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
324
|
Lu J, Wei Q, Bondy ML, Yu TK, Li D,
Brewster A, Shete S, Sahin A, Meric-Bernstam F and Wang LE:
Promoter polymorphism (−786t>C) in the endothelial nitric oxide
synthase gene is associated with risk of sporadic breast cancer in
non-Hispanic white women age younger than 55 years. Cancer.
107:2245–2253. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
325
|
Mortensen K, Holck S, Christensen IJ,
Skouv J, Hougaard DM, Blom J and Larsson LI: Endothelial cell
nitric oxide synthase in peritumoral microvessels is a favorable
prognostic indicator in premenopausal breast cancer patients. Clin
Cancer Res. 5:1093–1097. 1999.PubMed/NCBI
|
|
326
|
Mortensen K, Skouv J, Hougaard DM and
Larsson LI: Endogenous endothelial cell nitric-oxide synthase
modulates apoptosis in cultured breast cancer cells and is
transcriptionally regulated by p53. J Biol Chemistry.
274:37679–37684. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
327
|
Martin JH, Begum S, Alalami O, Harrison A
and Scott KW: Endothelial nitric oxide synthase: Correlation with
histologic grade, lymph node status and estrogen receptor
expression in human breast cancer. Tumour Biol. 21:90–97. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
328
|
Ramírez-Patiño R, Figuera LE, Puebla-Pérez
AM, Delgado-Saucedo JI, Legazpí-Macias MM, Mariaud-Schmidt RP,
Ramos-Silva A, Gutiérrez-Hurtado IA, Gómez Flores-Ramos L,
Zúñiga-González GM and Gallegos-Arreola MP: Intron 4 VNTR (4a/b)
polymorphism of the endothelial nitric oxide synthase gene is
associated with breast cancer in Mexican women. J Korean Med Sci.
28:1587–1594. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
329
|
Zintzaras E, Grammatikou M, Kitsios GD,
Doxani C, Zdoukopoulos N, Papandreou C and Patrikidou A:
Polymorphisms of the endothelial nitric oxide synthase gene in
breast cancer: A genetic association study and meta-analysis. J Hum
Genet. 55:743–748. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
330
|
Zhang L, Zeng M and Fu BM: Inhibition of
endothelial nitric oxide synthase decreases breast cancer cell
MDA-MB-231 adhesion to intact microvessels under physiological
flows. Am J Physiol Heart Circ Physiol. 310:H1735–H1747. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
331
|
Carkic J, Nikolic N, Nisevic J, Lazarevic
M, Kuzmanovic-Pficer J, Jelovac D and Milasin J: Endothelial nitric
oxide synthase polymorphisms/haplotypes are strong modulators of
oral cancer risk in Serbian population. J Oral Sci. 62:322–326.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
332
|
Karthik B, Shruthi DK, Singh J,
Tegginamani AS and Kudva S: Do tobacco stimulate the production of
nitric oxide by up regulation of inducible nitric oxide synthesis
in cancer: Immunohistochemical determination of inducible nitric
oxide synthesis in oral squamous cell carcinoma-a comparative study
in tobacco habituers and non-habituers. J Cancer Res Ther.
10:244–250. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
333
|
Chen Y, Li J, Guo Y and Guo XY: Nitric
oxide synthase 3 gene variants and colorectal cancer: A
meta-analysis. Asian Pac J Cancer Prev. 15:3811–3815. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
334
|
Mortensen K, Christensen IJ, Nielsen HJ,
Hansen U and Larsson LI: High expression of endothelial cell nitric
oxide synthase in peritumoral microvessels predicts increased
disease-free survival in colorectal cancer. Cancer Lett.
216:109–114. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
335
|
Peñarando J, López-Sánchez LM, Mena R,
Guil-Luna S, Conde F, Hernández V, Toledano M, Gudiño V, Raponi M,
Billard C, et al: A role for endothelial nitric oxide synthase in
intestinal stem cell proliferation and mesenchymal colorectal
cancer. BMC Biol. 16:32018. View Article : Google Scholar : PubMed/NCBI
|
|
336
|
Yeh CC, Santella RM, Hsieh LL, Sung FC and
Tang R: An intron 4 VNTR polymorphism of the endothelial nitric
oxide synthase gene is associated with early-onset colorectal
cancer. Int J Cancer. 124:1565–1571. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
337
|
Hefler LA, Ludwig E, Lampe D, Zeillinger
R, Leodolter S, Gitsch G, Koelbl H and Tempfer CB: Polymorphisms of
the endothelial nitric oxide synthase gene in ovarian cancer.
Gynecol Oncol. 86:134–137. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
338
|
Krishnaveni D, Amar Chand B, Shravan Kumar
P, Uma Devi M, Ramanna M, Jyothy A, Pratibha N, Balakrishna N and
Venkateshwari A: Association of endothelial nitric oxide synthase
gene T-786C promoter polymorphism with gastric cancer. World J
Gastrointest Oncol. 7:87–94. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
339
|
Wang L, Shi GG, Yao JC, Gong W, Wei D, Wu
TT, Ajani JA, Huang S and Xie K: Expression of endothelial nitric
oxide synthase correlates with the angiogenic phenotype of and
predicts poor prognosis in human gastric cancer. Gastric Cancer.
8:18–28. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
340
|
Tecder Ünal M, Karabulut HG, Gümüş-Akay G,
Dölen Y, Elhan A, Tükün A and Ünal AE: Endothelial nitric oxide
synthase gene polymorphism in gastric cancer. Turk J Gastroenterol.
21:338–344. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
341
|
de Fatima A, Zambuzzi WF, Modolo LV,
Tarsitano CA, Gadelha FR, Hyslop S, de Carvalho JE, Salgado I,
Ferreira CV and Pilli RA: Cytotoxicity of goniothalamin enantiomers
in renal cancer cells: Involvement of nitric oxide, apoptosis and
autophagy. Chem Biol Interact. 176:143–150. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
342
|
Hung WC, Wu TF, Ng SC, Lee YC, Shen HP,
Yang SF and Wang PH: Involvement of endothelial nitric oxide
synthase gene variants in the aggressiveness of uterine cervical
cancer. J Cancer. 10:2594–2600. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
343
|
Waheed S, Cheng RY, Casablanca Y, Maxwell
GL, Wink DA and Syed V: Nitric oxide donor DETA/NO inhibits the
growth of endometrial cancer cells by upregulating the expression
of RASSF1 and CDKN1A. Molecules. 24:37222019. View Article : Google Scholar : PubMed/NCBI
|
|
344
|
Riener EK, Hefler LA, Grimm C, Galid A,
Zeillinger R, Tong-Cacsire D, Gitsch G, Leodolter S and Tempfer CB:
Polymorphisms of the endothelial nitric oxide synthase gene in
women with vulvar cancer. Gynecol Oncol. 93:686–690. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
345
|
Wang J, Yang S, He P, Schetter AJ, Gaedcke
J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Gaida MM, et al:
Endothelial Nitric oxide synthase traffic inducer (NOSTRIN) is a
negative regulator of disease aggressiveness in pancreatic cancer.
Clin Cancer Res. 22:5992–6001. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
346
|
Yanar K, Cakatay U, Aydin S, Verim A,
Atukeren P, Özkan NE, Karatoprak K, Cebe T, Turan S, Ozkök E, et
al: Relation between endothelial nitric oxide synthase genotypes
and oxidative stress markers in larynx cancer. Oxid Med Cell
Longev. 2016:49850632016. View Article : Google Scholar : PubMed/NCBI
|
|
347
|
Chen C, Wang Y, Goh SS, Yang J, Lam DH,
Choudhury Y, Tay FC, Du S, Tan WK, Purwanti YI, et al: Inhibition
of neuronal nitric oxide synthase activity promotes migration of
human-induced pluripotent stem cell-derived neural stem cells
toward cancer cells. J Neurochem. 126:318–330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
348
|
Karihtala P, Soini Y, Auvinen P, Tammi R,
Tammi M and Kosma VM: Hyaluronan in breast cancer: Correlations
with nitric oxide synthases and tyrosine nitrosylation. J Histochem
Cytochem. 55:1191–1198. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
349
|
Lewko B, Zółtowska A, Stepiński J,
Kamiński M, Skokowski J, Roszkiewicz A and Moszkowska G: Nitric
oxide synthase type 1 expression in human lung cancer and its
relation to p53. Med Sci Monit. 7:218–221. 2001.PubMed/NCBI
|
|
350
|
Ahmed HH, Metwally FM, Mahdy ES, Shosha WG
and Ramadan SS: Clinical value of serum hepatocyte growth factor,
B-cell lymphoma-2 and nitric oxide in primary breast cancer
patients. Eur Rev Med Pharmacol Sci. 16:958–965. 2012.PubMed/NCBI
|
|
351
|
Al Dhaheri Y, Attoub S, Arafat K, Abuqamar
S, Viallet J, Saleh A, Al Agha H, Eid A and Iratni R:
Anti-metastatic and anti-tumor growth effects of Origanum majorana
on highly metastatic human breast cancer cells: Inhibition of NFκB
signaling and reduction of nitric oxide production. PLoS One.
8:e688082013. View Article : Google Scholar : PubMed/NCBI
|
|
352
|
Avtandilyan N, Javrushyan H, Petrosyan G
and Trchounian A: The involvement of arginase and nitric oxide
synthase in breast cancer development: Arginase and NO Synthase as
therapeutic targets in cancer. Biomed Res Int. 2018:86969232018.
View Article : Google Scholar : PubMed/NCBI
|
|
353
|
Bani D, Masini E, Bello MG, Bigazzi M and
Sacchi TB: Relaxin activates the L-arginine-nitric oxide pathway in
human breast cancer cells. Cancer Res. 55:5272–5275.
1995.PubMed/NCBI
|
|
354
|
Avtandilyan N, Javrushyan H, Karapetyan A
and Trchounian A: RETRACTED ARTICLE: Inhibition of tumor
progression by NG-Nitro-L-arginine Methyl Ester in
7,12-dimethylbenz(a)anthracene induced breast cancer: Nitric oxide
synthase inhibition as an antitumor prevention. J Mammary Gland
Biol Neoplasia. 24:1992019. View Article : Google Scholar : PubMed/NCBI
|
|
355
|
Alagol H, Erdem E, Sancak B, Turkmen G,
Camlibel M and Bugdayci G: Nitric oxide biosynthesis and
malondialdehyde levels in advanced breast cancer. Aust N Z J Surg.
69:647–650. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
356
|
Bhattacharjee KG, Bhattacharyya M, Halder
UC, Jana P and Sinha AK: The ‘Cross Talk’ between the receptors of
insulin, estrogen and progesterone in neutrophils in the synthesis
of maspin through nitric oxide in breast cancer. Int J Biomed Sci.
8:129–139. 2012.PubMed/NCBI
|
|
357
|
Cendan JC, Souba WW, Copeland EM III and
Lind DS: Increased L-arginine transport in a nitric oxide-producing
metastatic colon cancer cell line. Ann Surg Oncol. 3:501–508. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
358
|
Cendan JC, Topping DL, Pruitt J, Snowdy S,
Copeland EM III and Lind DS: Inflammatory mediators stimulate
arginine transport and arginine-derived nitric oxide production in
a murine breast cancer cell line. J Surg Res. 60:284–288. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
359
|
Chakraborty S, Girish GV and Sinha AK:
Impaired binding of insulin to erythrocyte membrane receptor and
the activation of nitric oxide synthase by the hormone in human
breast cancer. J Cancer Res Clin Oncol. 130:294–300. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
360
|
Coskun U, Gunel N, Sancak B, Günel U, Onuk
E, Bayram O, Yílmaz E, Candan S and Ozkan S: Significance of serum
vascular endothelial growth factor, insulin-like growth factor-I
levels and nitric oxide activity in breast cancer patients. Breast.
12:104–110. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
361
|
Coskun U, Gunel N, Sancak B, Günel U, Onuk
E, Bayram O, Yílmaz E, Candan S and Ozkan S: WITHDRAWN:
Significance of serum vascular endothelial growth factor,
insulin-like growth factor-I levels and nitric oxide activity in
breast cancer patients. Breast. Aug 20–2008.doi:
10.1054/brst.2002.0483 (Epub ahead of print). PubMed/NCBI
|
|
362
|
Dave B, Granados-Principal S, Zhu R, Benz
S, Rabizadeh S, Soon-Shiong P, Yu KD, Shao Z, Li X, Gilcrease M, et
al: Targeting RPL39 and MLF2 reduces tumor initiation and
metastasis in breast cancer by inhibiting nitric oxide synthase
signaling. Proc Natl Acad Sci USA. 111:8838–8843. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
363
|
De Vitto H, Mendonca BS, Elseth KM, Onul
A, Xue J, Vesper BJ, Gallo CV, Rumjanek FD, Paradise WA and
Radosevich JA: Part III. Molecular changes induced by high nitric
oxide adaptation in human breast cancer cell line BT-20
(BT-20-HNO): A switch from aerobic to anaerobic metabolism. Tumour
Biol. 34:403–413. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
364
|
Deliconstantinos G, Villiotou V, Stavrides
JC, Salemes N and Gogas J: Nitric oxide and peroxynitrite
production by human erythrocytes: A causative factor of toxic
anemia in breast cancer patients. Anticancer Res. 15:1435–1446.
1995.PubMed/NCBI
|
|
365
|
Demircan B, Yucel B and Radosevich JA: DNA
methylation in human breast cancer cell lines adapted to high
nitric oxide. In Vivo. 34:169–176. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
366
|
Duan L, Danzer B, Levenson VV and Maki CG:
Critical roles for nitric oxide and ERK in the completion of
prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive
breast cancer cells. Cancer Lett. 353:290–300. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
367
|
El Hasasna H, Saleh A, Al Samri H,
Athamneh K, Attoub S, Arafat K, Benhalilou N, Alyan S, Viallet J,
Al Dhaheri Y, et al: Rhus coriaria suppresses angiogenesis,
metastasis and tumor growth of breast cancer through inhibition of
STAT3, NFκB and nitric oxide pathways. Scic Rep. 6:211442016.
View Article : Google Scholar : PubMed/NCBI
|
|
368
|
Engelen M, Klimberg VS, Allasia A and
Deutz NEP: Major surgery diminishes systemic arginine availability
and suppresses nitric oxide response to feeding in patients with
early stage breast cancer. Clin Nutr. 37:1645–1653. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
369
|
Erbas H, Aydogdu N, Usta U and Erten O:
Protective role of carnitine in breast cancer via decreasing
arginase activity and increasing nitric oxide. Cell Biol Int.
31:1414–1419. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
370
|
Gaballah HE, Abdel Salam I, Abdel Wahab N
and Mansour OM: Plasma bcl-2 and nitric oxide: Possible prognostic
role in patients with metastatic breast cancer. Med Oncol.
18:171–178. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
371
|
Gajalakshmi P, Priya MK, Pradeep T, Behera
J, Muthumani K, Madhuwanti S, Saran U and Chatterjee S: Breast
cancer drugs dampen vascular functions by interfering with nitric
oxide signaling in endothelium. Toxicol Appl Pharmacol.
269:121–131. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
372
|
Ganguly Bhattacharjee K, Bhattacharyya M,
Halder UC, Jana P and Sinha AK: The role of neutrophil estrogen
receptor status on maspin synthesis via nitric oxide production in
human breast cancer. J Breast Cancer. 15:181–188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
373
|
Ganguly Bhattacharjee K, Bhattacharyya M,
Halder UC, Jana P and Sinha AK: Effect of progesterone receptor
status on maspin synthesis via nitric oxide production in
neutrophils in human breast cancer. Breast Cancer. 21:605–613.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
374
|
Gaspari APS, da Silva RS, Carneiro ZA, de
Carvalho MR, Carvalho I, Pernomian L, Ferreira LP, Ramos LCB, de
Souza GA and Formiga ALB: Improving cytotoxicity against breast
cancer cells by using Mixed-Ligand Ruthenium(II) Complexes of
2,2′-Bipyridine, amino acid, and nitric oxide derivatives as
potential anticancer agents. Anticancer Agents Med Chem.
21:1602–1611. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
375
|
Guha M, Biswas J, Tirkey J and Sinha AK:
Impairment of stimulation by estrogen of insulin-activated nitric
oxide synthase in human breast cancer. Int J Cancer. 100:261–265.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
376
|
Günel N, Coskun U, Sancak B, Hasdemir O,
Sare M, Bayram O, Celenkoglu G and Ozkan S: Prognostic value of
serum IL-18 and nitric oxide activity in breast cancer patients at
operable stage. Am J Clin Oncol. 26:416–421. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
377
|
Kampa M, Hatzoglou A, Notas G, Niniraki M,
Kouroumalis E and Castanas E: Opioids are non-competitive
inhibitors of nitric oxide synthase in T47D human breast cancer
cells. Cell Death Differ. 8:943–952. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
378
|
Khalkhali-Ellis Z and Hendrix MJ: Nitric
oxide regulation of maspin expression in normal mammary epithelial
and breast cancer cells. Am J Pathol. 162:1411–1417. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
379
|
Konukoglu D, Turhan MS, Celik V and Turna
H: Relation of serum vascular endothelial growth factor as an
angiogenesis biomarker with nitric oxide & urokinase-type
plasminogen activator in breast cancer patients. Indian J Med Res.
125:747–751. 2007.PubMed/NCBI
|
|
380
|
Kumar S and Kashyap P: Antiproliferative
activity and nitric oxide production of a methanolic extract of
Fraxinus micrantha on Michigan Cancer Foundation-7 mammalian breast
carcinoma cell line. J Intercult Ethnopharmacol. 4:109–113. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
381
|
Lahiri M and Martin JH: Nitric oxide
decreases motility and increases adhesion in human breast cancer
cells. Oncol Rep. 21:275–281. 2009.PubMed/NCBI
|
|
382
|
Lee SY, Rim Y, McPherson DD, Huang SL and
Kim H: A novel liposomal nanomedicine for nitric oxide delivery and
breast cancer treatment. Biomed Mater Eng. 24:61–67.
2014.PubMed/NCBI
|
|
383
|
Hewala TI, Abd El-Moneim NA, Ebied SA,
Sheta MI, Soliman K and Abu-Elenean A: Diagnostic and prognostic
value of serum nitric oxide, tumor necrosis factor-alpha, basic
fibroblast growth factor and copper as angiogenic markers in
premenopausal breast cancer patients: A case-control study. Br J
Biomed Sci. 67:167–176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
384
|
Finkelman BS, Putt M, Wang T, Wang L,
Narayan H, Domchek S, DeMichele A, Fox K, Matro J, Shah P, et al:
Arginine-nitric oxide metabolites and cardiac dysfunction in
patients with breast cancer. J Am Coll Cardiol. 70:152–162. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
385
|
Jadeski LC, Chakraborty C and Lala PK:
Role of nitric oxide in tumour progression with special reference
to a murine breast cancer model. Can J Physiol Pharmacol.
80:125–135. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
386
|
McCurdy MR, Wazni MW, Martinez J, McAleer
MF and Guerrero T: Exhaled nitric oxide predicts radiation
pneumonitis in esophageal and lung cancer patients receiving
thoracic radiation. Radiother Oncol. 101:443–448. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
387
|
Metwally FM, El-mezayen HA and Ahmed HH:
Significance of vascular endothelial growth factor, interleukin-18
and nitric oxide in patients with breast cancer: Correlation with
carbohydrate antigen 15.3. Med Oncol. 28 (Suppl 1):S15–S21. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
388
|
Mishra D, Patel V and Banerjee D: Nitric
Oxide and S-Nitrosylation in Cancers: Emphasis on breast cancer.
Breast Cancer (Auckl). 14:11782234198826882020.PubMed/NCBI
|
|
389
|
Nakamura Y, Yasuoka H, Tsujimoto M,
Yoshidome K, Nakahara M, Nakao K, Nakamura M and Kakudo K: Nitric
oxide in breast cancer: Induction of vascular endothelial growth
factor-C and correlation with metastasis and poor prognosis. Clin
Cancer Res. 12:1201–1207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
390
|
Negroni MP, Fiszman GL, Azar ME, Morgado
CC, Español AJ, Pelegrina LT, de la Torre E and Sales ME:
Immunoglobulin G from breast cancer patients in stage I stimulates
muscarinic acetylcholine receptors in MCF7 cells and induces
proliferation. Participation of nitric oxide synthase-derived
nitric oxide. J Clin Immunol. 30:474–484. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
391
|
Martin JH, Alalami O and Yaqoob F:
Differential effects of retinoids on nitric oxide production by
promonocytic U937 cells and ZR-75-1 human breast cancer cells.
Oncol Rep. 7:219–223. 2000.PubMed/NCBI
|
|
392
|
Martin JH, Symonds A and Chohan S:
Down-regulation of nitric oxide production by droloxifene and
toremifene in human breast cancer cells. Oncol Rep. 10:979–984.
2003.PubMed/NCBI
|
|
393
|
Nath N, Chattopadhyay M, Rodes DB,
Nazarenko A, Kodela R and Kashfi K: Nitric Oxide-releasing aspirin
suppresses NF-κB signaling in estrogen receptor negative breast
cancer cells in vitro and in vivo. Molecules. 20:12481–12499. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
394
|
Pance A: Nitric oxide and hormones in
breast cancer: Allies or enemies? Future Oncol. 2:275–288. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
395
|
Parihar A, Parihar MS and Ghafourifar P:
Significance of mitochondrial calcium and nitric oxide for
apoptosis of human breast cancer cells induced by tamoxifen and
etoposide. Int J Mol Med. 21:317–324. 2008.PubMed/NCBI
|
|
396
|
Pervin S, Singh R and Chaudhuri G: Nitric
oxide-induced cytostasis and cell cycle arrest of a human breast
cancer cell line (MDA-MB-231): Potential role of cyclin D1. Proc
Natl Acad Sci USA. 98:3583–3588. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
397
|
Pervin S, Singh R and Chaudhuri G: Nitric
oxide, N omega-hydroxy-L-arginine and breast cancer. Nitric Oxide.
19:103–106. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
398
|
Pervin S, Singh R, Freije WA and Chaudhuri
G: MKP-1-induced dephosphorylation of extracellular
signal-regulated kinase is essential for triggering nitric
oxide-induced apoptosis in human breast cancer cell lines:
Implications in breast cancer. Cancer Res. 63:8853–8860.
2003.PubMed/NCBI
|
|
399
|
Pervin S, Singh R, Gau CL, Edamatsu H,
Tamanoi F and Chaudhuri G: Potentiation of nitric oxide-induced
apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor:
Implications in breast cancer. Cancer Res. 61:4701–4706.
2001.PubMed/NCBI
|
|
400
|
Pervin S, Singh R, Hernandez E, Wu G and
Chaudhuri G: Nitric oxide in physiologic concentrations targets the
translational machinery to increase the proliferation of human
breast cancer cells: Involvement of mammalian target of
rapamycin/eIF4E pathway. Cancer Res. 67:289–299. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
401
|
Punathil T, Tollefsbol TO and Katiyar SK:
EGCG inhibits mammary cancer cell migration through inhibition of
nitric oxide synthase and guanylate cyclase. Biochem Biophys Res
Commun. 375:162–167. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
402
|
Radisavljevic Z: Inactivated tumor
suppressor Rb by nitric oxide promotes mitosis in human breast
cancer cells. J Cell Biochem. 92:1–5. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
403
|
Rashad YA, Elkhodary TR, El-Gayar AM and
Eissa LA: Evaluation of serum levels of HER2, MMP-9, Nitric Oxide,
and total antioxidant capacity in egyptian breast cancer patients:
Correlation with clinico-pathological parameters. Sci Pharm.
82:129–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
404
|
Ray GN, Shahid M and Husain SA: Effect of
nitric oxide and malondialdehyde on sister-chromatid exchanges in
breast cancer. Br J Biomed Sci. 58:169–176. 2001.PubMed/NCBI
|
|
405
|
Reveneau S, Arnould L, Jolimoy G, Hilpert
S, Lejeune P, Saint-Giorgio V, Belichard C and Jeannin JF: Nitric
oxide synthase in human breast cancer is associated with tumor
grade, proliferation rate, and expression of progesterone
receptors. Lab Invest. 79:1215–1225. 1999.PubMed/NCBI
|
|
406
|
Ridnour LA, Barasch KM, Windhausen AN,
Dorsey TH, Lizardo MM, Yfantis HG, Lee DH, Switzer CH, Cheng RY,
Heinecke JL, et al: Nitric oxide synthase and breast cancer: Role
of TIMP-1 in NO-mediated Akt activation. PLoS One. 7:e440812012.
View Article : Google Scholar : PubMed/NCBI
|
|
407
|
Zhu W, Yang B, Fu H, Ma L, Liu T, Chai R,
Zheng Z, Zhang Q and Li G: Flavone inhibits nitric oxide synthase
(NOS) activity, nitric oxide production and protein S-nitrosylation
in breast cancer cells. Biochem Biophys Res Commun. 458:590–595.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
408
|
Zheng X, Fernando V, Sharma V, Walia Y,
Letson J and Furuta S: Correction of arginine metabolism with
sepiapterin-the precursor of nitric oxide synthase cofactor
BH(4)-induces immunostimulatory-shift of breast cancer. Biochem
Pharmacol. 176:1138872020. View Article : Google Scholar : PubMed/NCBI
|
|
409
|
Zeillinger R, Tantscher E, Schneeberger C,
Tschugguel W, Eder S, Sliutz G and Huber JC: Simultaneous
expression of nitric oxide synthase and estrogen receptor in human
breast cancer cell lines. Breast Cancer Res Treat. 40:205–207.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
410
|
Wang HJ, Wei XF, Jiang YY, Huang H, Yang
Y, Fan SM, Zang LH, Tashiro S, Onodera S and Ikejima T: Silibinin
induces the generation of nitric oxide in human breast cancer MCF-7
cells. Free Radic Res. 44:577–584. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
411
|
Thamrongwittawatpong L, Sirivatanauksorn
Y, Batten JJ, Williamson RC, Kakkar AK and Mathie RT: The effect of
N(G)-monomethyl-L-arginine and tamoxifen on nitric oxide production
in breast cancer cells stimulated by oestrogen and progesterone.
Eur J Surg. 167:484–489. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
412
|
Toomey D, Condron C, Wu QD, Kay E, Harmey
J, Broe P, Kelly C and Bouchier-Hayes D: TGF-beta1 is elevated in
breast cancer tissue and regulates nitric oxide production from a
number of cellular sources during hypoxia re-oxygenation injury. Br
J Biomed Sci. 58:177–183. 2001.PubMed/NCBI
|
|
413
|
Salaroglio IC, Gazzano E, Abdullrahman A,
Mungo E, Castella B, Abd-Elrahman GEFA, Massaia M, Donadelli M,
Rubinstein M, Riganti C and Kopecka J: Increasing intratumor
C/EBP-β LIP and nitric oxide levels overcome resistance to
doxorubicin in triple negative breast cancer. J Exp Clin Cancer
Res. 37:2862018. View Article : Google Scholar : PubMed/NCBI
|
|
414
|
Sen S, Kawahara B and Chaudhuri G:
Mitochondrial-associated nitric oxide synthase activity inhibits
cytochrome c oxidase: Implications for breast cancer. Free Radic
Biol Med. 57:210–220. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
415
|
Sen S, Kawahara B, Fukuto J and Chaudhuri
G: Induction of a feed forward pro-apoptotic mechanistic loop by
nitric oxide in a human breast cancer model. PLoS One.
8:e705932013. View Article : Google Scholar : PubMed/NCBI
|
|
416
|
Shoulars K, Rodriguez MA, Thompson T, Turk
J, Crowley J and Markaverich BM: Regulation of the nitric oxide
pathway genes by tetrahydrofurandiols: Microarray analysis of MCF-7
human breast cancer cells. Cancer Lett. 264:265–273. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
417
|
Simeone AM, Broemeling LD, Rosenblum J and
Tari AM: HER2/neu reduces the apoptotic effects of
N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by
decreasing nitric oxide production. Oncogene. 22:6739–6747. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
418
|
Simeone AM, Ekmekcioglu S, Broemeling LD,
Grimm EA and Tari AM: A novel mechanism by which
N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth:
The production of nitric oxide. Mol Cancer Ther. 1:1009–1017.
2002.PubMed/NCBI
|
|
419
|
Simeone AM, McMurtry V, Nieves-Alicea R,
Saavedra JE, Keefer LK, Johnson MM and Tari AM: TIMP-2 mediates the
anti-invasive effects of the nitric oxide-releasing prodrug JS-K in
breast cancer cells. Breast Cancer Res. 10:R442008. View Article : Google Scholar : PubMed/NCBI
|
|
420
|
Singh T and Katiyar SK: Honokiol, a
phytochemical from Magnolia spp., inhibits breast cancer cell
migration by targeting nitric oxide and cyclooxygenase-2. Int J
Oncol. 38:769–776. 2011.PubMed/NCBI
|
|
421
|
Smeda M, Kieronska A, Adamski MG,
Proniewski B, Sternak M, Mohaissen T, Przyborowski K, Derszniak K,
Kaczor D, Stojak M, et al: Nitric oxide deficiency and
endothelial-mesenchymal transition of pulmonary endothelium in the
progression of 4T1 metastatic breast cancer in mice. Breast Cancer
Res. 20:862018. View Article : Google Scholar : PubMed/NCBI
|
|
422
|
Song YK, Billiar TR and Lee YJ: Role of
galectin-3 in breast cancer metastasis: Involvement of nitric
oxide. Am J Pathol. 160:1069–1075. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
423
|
Switzer CH, Cheng RY, Ridnour LA, Glynn
SA, Ambs S and Wink DA: Ets-1 is a transcriptional mediator of
oncogenic nitric oxide signaling in estrogen receptor-negative
breast cancer. Breast Cancer Res. 14:R1252012. View Article : Google Scholar : PubMed/NCBI
|
|
424
|
Switzer CH, Glynn SA, Ridnour LA, Cheng
RY, Vitek MP, Ambs S and Wink DA: Nitric oxide and protein
phosphatase 2A provide novel therapeutic opportunities in
ER-negative breast cancer. Trends Pharmacol Sci. 32:644–651. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
425
|
Ai Y, Kang F, Huang Z, Xue X, Lai Y, Peng
S, Tian J and Zhang Y: Synthesis of CDDO-amino acid-nitric oxide
donor trihybrids as potential antitumor agents against both
drug-sensitive and drug-resistant colon cancer. J Med Chem.
58:2452–2464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
426
|
Babykutty S, Suboj P, Srinivas P, Nair AS,
Chandramohan K and Gopala S: Insidious role of nitric oxide in
migration/invasion of colon cancer cells by upregulating MMP-2/9
via activation of cGMP-PKG-ERK signaling pathways. Clin Exp
Metastasis. 29:471–492. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
427
|
Bessa X, Elizalde JI, Mitjans F, Piñol V,
Miquel R, Panés J, Piulats J, Piqué JM and Castells A: Leukocyte
recruitment in colon cancer: Role of cell adhesion molecules,
nitric oxide, and transforming growth factor beta1.
Gastroenterology. 122:1122–1132. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
428
|
Chattopadhyay M, Kodela R, Olson KR and
Kashfi K: NOSH-aspirin (NBS-1120), a novel nitric oxide- and
hydrogen sulfide-releasing hybrid is a potent inhibitor of colon
cancer cell growth in vitro and in a xenograft mouse model. Biochem
Biophys Res Commun. 419:523–528. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
429
|
Edes K, Cassidy P, Shami PJ and Moos PJ:
JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon
cancer cells with knockdown of thioredoxin reductase 1. PLoS One.
5:e87862010. View Article : Google Scholar : PubMed/NCBI
|
|
430
|
Ishikawa T, Yoshida N, Higashihara H,
Inoue M, Uchiyama K, Takagi T, Handa O, Kokura S, Naito Y, Okanoue
T and Yoshikawa T: Different effects of constitutive nitric oxide
synthase and heme oxygenase on pulmonary or liver metastasis of
colon cancer in mice. Clin Exp Metastasis. 20:445–450. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
431
|
Jarry A, Charrier L, Bou-Hanna C, Devilder
MC, Crussaire V, Denis MG, Vallette G and Laboisse CL: Position in
cell cycle controls the sensitivity of colon cancer cells to nitric
oxide-dependent programmed cell death. Cancer Res. 64:4227–4234.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
432
|
Jenkins DC, Charles IG, Baylis SA, Lelchuk
R, Radomski MW and Moncada S: Human colon cancer cell lines show a
diverse pattern of nitric oxide synthase gene expression and nitric
oxide generation. Br J Cancer. 70:847–849. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
433
|
Jeon HK, Choi SU and Jung NP: Association
of the ERK1/2 and p38 kinase pathways with nitric oxide-induced
apoptosis and cell cycle arrest in colon cancer cells. Cell Biol
Toxicol. 21:115–125. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
434
|
Kim MY: Sasa quelpaertensis Nakai extract
induces p53-independent apoptosis via the elevation of nitric oxide
production in human HCT116 colon cancer cells. Oncol Lett.
19:3027–3034. 2020.PubMed/NCBI
|
|
435
|
Kopecka J, Campia I, Brusa D, Doublier S,
Matera L, Ghigo D, Bosia A and Riganti C: Nitric oxide and
P-glycoprotein modulate the phagocytosis of colon cancer cells. J
Cell Mol Med. 15:1492–1504. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
436
|
Liu Q, Chan ST and Mahendran R: Nitric
oxide induces cyclooxygenase expression and inhibits cell growth in
colon cancer cell lines. Carcinogenesis. 24:637–642. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
437
|
Liu Q, Inoue H and Mahendran R:
Transcriptional regulation of the COX-2 expression by nitric oxide
in colon cancer cell lines. Oncol Rep. 19:269–274. 2008.PubMed/NCBI
|
|
438
|
Mojic M, Mijatovic S, Maksimovic-Ivanic D,
Miljkovic D, Stosic-Grujicic S, Stankovic M, Mangano K, Travali S,
Donia M, Fagone P, et al: Therapeutic potential of nitric
oxide-modified drugs in colon cancer cells. Mol Pharmacol.
82:700–710. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
439
|
Millet A, Bettaieb A, Renaud F, Prevotat
L, Hammann A, Solary E, Mignotte B and Jeannin JF: Influence of the
nitric oxide donor glyceryl trinitrate on apoptotic pathways in
human colon cancer cells. Gastroenterology. 123:235–246. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
440
|
Oláh G, Módis K, Törö G, Hellmich MR,
Szczesny B and Szabo C: Role of endogenous and exogenous nitric
oxide, carbon monoxide and hydrogen sulfide in HCT116 colon cancer
cell proliferation. Biochem Pharmacol. 149:186–204. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
441
|
Prevotat L, Filomenko R, Solary E, Jeannin
JF and Bettaieb A: Nitric oxide-induced down-regulation of
beta-catenin in colon cancer cells by a proteasome-independent
specific pathway. Gastroenterology. 131:1142–1152. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
442
|
Rao CV: Nitric oxide signaling in colon
cancer chemoprevention. Mutation Res. 555:107–119. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
443
|
Rao CV, Reddy BS, Steele VE, Wang CX, Liu
X, Ouyang N, Patlolla JM, Simi B, Kopelovich L and Rigas B: Nitric
oxide-releasing aspirin and indomethacin are potent inhibitors
against colon cancer in azoxymethane-treated rats: Effects on
molecular targets. Mol Cancer Ther. 5:1530–1538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
444
|
Riganti C, Miraglia E, Viarisio D,
Costamagna C, Pescarmona G, Ghigo D and Bosia A: Nitric oxide
reverts the resistance to doxorubicin in human colon cancer cells
by inhibiting the drug efflux. Cancer Res. 65:516–525.
2005.PubMed/NCBI
|
|
445
|
Wang H and MacNaughton WK: Overexpressed
beta-catenin blocks nitric oxide-induced apoptosis in colonic
cancer cells. Cancer Res. 65:8604–8607. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
446
|
Xie J, Xia L, Xiang W, He W, Yin H, Wang
F, Gao T, Qi W, Yang Z, Yang X, et al: Metformin selectively
inhibits metastatic colorectal cancer with the KRAS mutation by
intracellular accumulation through silencing MATE1. Proc Natl Acad
Sci USA. 117:13012–13022. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
447
|
Wenzel U, Kuntz S, De Sousa UJ and Daniel
H: Nitric oxide suppresses apoptosis in human colon cancer cells by
scavenging mitochondrial superoxide anions. Int J Cancer.
106:666–675. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
448
|
Williams JL, Borgo S, Hasan I, Castillo E,
Traganos F and Rigas B: Nitric oxide-releasing nonsteroidal
anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon
cancer cell lines more effectively than traditional NSAIDs:
Implications for colon cancer chemoprevention. Cancer Res.
61:3285–3289. 2001.PubMed/NCBI
|
|
449
|
Voss NCS, Kold-Petersen H and Boedtkjer E:
Enhanced nitric oxide signaling amplifies vasorelaxation of human
colon cancer feed arteries. Am J Physiol Heart Circ Physiol.
316:H245–H254. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
450
|
Tesei A, Rosetti M, Ulivi P, Fabbri F,
Medri L, Vannini I, Bolla M, Amadori D and Zoli W: Study of
molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel
nitric oxide-releasing aspirin, in colon cancer cell lines. J
Transl Med. 5:522007. View Article : Google Scholar : PubMed/NCBI
|
|
451
|
Thomsen LL, Miles DW, Happerfield L,
Bobrow LG, Knowles RG and Moncada S: Nitric oxide synthase activity
in human breast cancer. Br J Cancer. 72:41–44. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
452
|
Stettner N, Rosen C, Bernshtein B,
Gur-Cohen S, Frug J, Silberman A, Sarver A, Carmel-Neiderman NN,
Eilam R, Biton I, et al: Induction of Nitric-Oxide metabolism in
enterocytes alleviates colitis and inflammation-associated colon
cancer. Cell Rep. 23:1962–1976. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
453
|
Ambs S, Bennett WP, Merriam WG, Ogunfusika
MO, Oser SM, Khan MA, Jones RT and Harris CC: Vascular endothelial
growth factor and nitric oxide synthase expression in human lung
cancer and the relation to p53. Br J Ccancer. 78:233–239. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
454
|
Cembrzynska-Nowak M, Bienkowska M and
Szklarz E: Exogenous interleukin 2 regulates interleukin 6 and
nitric oxide but not interferon gamma and tumor necrosis factor
alpha production in bronchoalveolar leukocytes from patients with
small cell lung cancer. Arch Immunol Ther Exp (Warsz). 46:367–374.
1998.PubMed/NCBI
|
|
455
|
Cembrzyńska-Nowak M, Bieńkowska M,
Weryńska B, Dyła T and Jankowska R: The contribution of endotoxins
present in the respiratory tract to overproduction of nitric oxide
associated with impaired interleukin 6 release in bronchoalveolar
leukocytes from lung cancer patients. Arch Immunol Ther Exp
(Warsz). 48:119–125. 2000.PubMed/NCBI
|
|
456
|
Chen Z, Huang KY, Ling Y, Goto M, Duan HQ,
Tong XH, Liu YL, Cheng YY, Morris-Natschke SL, Yang PC, et al:
Discovery of an Oleanolic Acid/Hederagenin-nitric oxide donor
hybrid as an EGFR tyrosine kinase inhibitor for non-small-cell lung
cancer. J Natural Prod. 82:3065–3073. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
457
|
Deliu Z, Tamas T, Chowdhury J, Aqil M,
Bassiony M and Radosevich JA: Expression of cross-tolerance to a
wide range of conditions in a human lung cancer cell line after
adaptation to nitric oxide. Tumour Biol. 39:10104283177237782017.
View Article : Google Scholar : PubMed/NCBI
|
|
458
|
Fu J, Han J, Meng T, Hu J and Yin J: Novel
α-ketoamide based diazeniumdiolates as hydrogen peroxide responsive
nitric oxide donors with anti-lung cancer activity. Chem Commun
(Camb). 55:12904–12907. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
459
|
Fujimoto H, Ando Y, Yamashita T, Terazaki
H, Tanaka Y, Sasaki J, Matsumoto M, Suga M and Ando M: Nitric oxide
synthase activity in human lung cancer. Jpn J Cancer Res.
88:1190–1198. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
460
|
Gao X, Xuan Y, Benner A, Anusruti A,
Brenner H and Schottker B: Nitric oxide metabolites and lung cancer
incidence: A matched case-control study nested in the ESTHER
cohort. Oxid Med Cell Longev. 2019:64709502019. View Article : Google Scholar : PubMed/NCBI
|
|
461
|
Hwang JH, Park SJ, Ko WG, Kang SM, Lee DB,
Bang J, Park BJ, Wee CB, Kim DJ, Jang IS and Ko JH: Cordycepin
induces human lung cancer cell apoptosis by inhibiting nitric oxide
mediated ERK/Slug signaling pathway. Am J Cancer Res. 7:417–432.
2017.PubMed/NCBI
|
|
462
|
Kaynar H, Meral M, Turhan H, Keles M,
Celik G and Akcay F: Glutathione peroxidase,
glutathione-S-transferase, catalase, xanthine oxidase, Cu-Zn
superoxide dismutase activities, total glutathione, nitric oxide,
and malondialdehyde levels in erythrocytes of patients with small
cell and non-small cell lung cancer. Cancer Lett. 227:133–139.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
463
|
Koizumi M, Yamazaki H, Toyokawa K,
Yoshioka Y, Suzuki G, Ito M, Shinkawa K, Nishino K, Watanabe Y,
Inoue T, et al: Influence of thoracic radiotherapy on exhaled
nitric oxide levels in patients with lung cancer. Jpn J Clin Oncol.
31:142–146. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
464
|
Munaweera I, Shi Y, Koneru B, Patel A,
Dang MH, Di Pasqua AJ and Balkus KJ Jr: Nitric oxide- and
cisplatin-releasing silica nanoparticles for use against non-small
cell lung cancer. J Inorg Biochem. 153:23–31. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
465
|
Maciag AE, Chakrapani H, Saavedra JE,
Morris NL, Holland RJ, Kosak KM, Shami PJ, Anderson LM and Keefer
LK: The nitric oxide prodrug JS-K is effective against
non-small-cell lung cancer cells in vitro and in vivo: Involvement
of reactive oxygen species. J Pharmacol Exp Ther. 336:313–320.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
466
|
Maiuthed A, Prakhongcheep O and
Chanvorachote P: Microarray-based analysis of genes, transcription
factors, and epigenetic modifications in lung cancer exposed to
nitric oxide. Cancer Genom Proteomics. 17:401–415. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
467
|
Lee JJ, Kwon HK, Lee DS, Lee SW, Lee KK,
Kim KJ and Kim JL: Mycelial extract of phellinus linteus induces
cell death in A549 lung cancer cells and elevation of nitric oxide
in raw 264.7 macrophage cells. Mycobiology. 34:143–147. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
468
|
Liaw YP, Ting TF, Ho CC and Chiou ZY: Cell
type specificity of lung cancer associated with nitric oxide. Sci
Total Environ. 408:4931–4934. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
469
|
Liu PF, Zhao DH, Qi Y, Wang JG, Zhao M,
Xiao K and Xie LX: The clinical value of exhaled nitric oxide in
patients with lung cancer. Clin Respir J. 12:23–30. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
470
|
Luanpitpong S and Chanvorachote P: Nitric
oxide and aggressive behavior of lung cancer cells. Anticancer Res.
35:4585–4592. 2015.PubMed/NCBI
|
|
471
|
Muto S, Takagi H, Owada Y, Inoue T,
Watanabe Y, Yamaura T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa
T, et al: Serum nitric oxide as a predictive biomarker for
bevacizumab in non-small cell lung cancer patients. Anticancer Res.
37:3169–3174. 2017.PubMed/NCBI
|
|
472
|
Masri F: Role of nitric oxide and its
metabolites as potential markers in lung cancer. Ann Thorac Med.
5:123–127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
473
|
Masri FA, Comhair SA, Koeck T, Xu W,
Janocha A, Ghosh S, Dweik RA, Golish J, Kinter M, Stuehr DJ, et al:
Abnormalities in nitric oxide and its derivatives in lung cancer.
Am J Respir Crit Care Med. 172:597–605. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
474
|
Matsunaga T, Yamaji Y, Tomokuni T, Morita
H, Morikawa Y, Suzuki A, Yonezawa A, Endo S, Ikari A, Iguchi K, et
al: Nitric oxide confers cisplatin resistance in human lung cancer
cells through upregulation of aldo-keto reductase 1B10 and
proteasome. Free Radical Res. 48:1371–1385. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
475
|
Powan P and Chanvorachote P: Nitric oxide
mediates cell aggregation and mesenchymal to epithelial transition
in anoikis-resistant lung cancer cells. Mol Cell Biochem.
393:237–245. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
476
|
Punathil T and Katiyar SK: Inhibition of
non-small cell lung cancer cell migration by grape seed
proanthocyanidins is mediated through the inhibition of nitric
oxide, guanylate cyclase, and ERK1/2. Mol Carcinog. 48:232–242.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
477
|
Zhou J, Zhu Q and Yao H: Chemotherapy of
non-small-cell lung cancer (NSCLC) and changes in serum sAPO-1/Fas
and nitric oxide (NO) levels. Zhonghua Zhong Liu Za Zhi.
22:225–227. 2000.(In Chinese). PubMed/NCBI
|
|
478
|
Zhou H, Dong Y, Ma X, Xu J and Xu S:
Development of a novel truncated deguelin derivative possessing
nitric oxide donor as a potential anti-lung cancer agent.
Fitoterapia. 146:1046702020. View Article : Google Scholar : PubMed/NCBI
|
|
479
|
Zhang L, Liu J, Wang X, Li Z, Zhang X, Cao
P, She X, Dai Q, Tang J and Liu Z: Upregulation of cytoskeleton
protein and extracellular matrix protein induced by stromal-derived
nitric oxide promotes lung cancer invasion and metastasis. Curr Mol
Med. 14:762–771. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
480
|
Yongsanguanchai N, Pongrakhananon V,
Mutirangura A, Rojanasakul Y and Chanvorachote P: Nitric oxide
induces cancer stem cell-like phenotypes in human lung cancer
cells. Am J Physiol Cell Physiol. 308:C89–C100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
481
|
Wongvaranon P, Pongrakhananon V, Chunhacha
P and Chanvorachote P: Acquired resistance to chemotherapy in lung
cancer cells mediated by prolonged nitric oxide exposure.
Anticancer Res. 33:5433–5444. 2013.PubMed/NCBI
|
|
482
|
Saisongkorh V, Maiuthed A and
Chanvorachote P: Nitric oxide increases the migratory activity of
non-small cell lung cancer cells via AKT-mediated integrin αv and
β1 upregulation. Cell Oncol (Dordr). 39:449–462. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
483
|
Saleem W, Suzuki Y, Mobaraki A, Yoshida Y,
Noda S, Saitoh JI and Nakano T: Reduction of nitric oxide level
enhances the radiosensitivity of hypoxic non-small cell lung
cancer. Cancer Sci. 102:2150–2156. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
484
|
Sanuphan A, Chunhacha P, Pongrakhananon V
and Chanvorachote P: Long-term nitric oxide exposure enhances lung
cancer cell migration. Biomed Res Int. 2013:1869722013. View Article : Google Scholar : PubMed/NCBI
|
|
485
|
Sanuphan A, Chunhacha P, Pongrakhananon V
and Chanvorachote P: Corrigendum to ‘Long-term nitric oxide
exposure enhances lung cancer cell migration’. Biomed Res Int.
2015:3106362015. View Article : Google Scholar : PubMed/NCBI
|
|
486
|
Su X, Takahashi A, Guo G, Mori E, Okamoto
N, Ohnishi K, Iwasaki T and Ohnishi T: Biphasic effects of nitric
oxide radicals on radiation-induced lethality and chromosome
aberrations in human lung cancer cells carrying different p53 gene
status. Int J Radiat Oncol Biol Phys. 77:559–565. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
487
|
Suzuki Y, Inui N, Karayama M, Imokawa S,
Yamada T, Yokomura K, Asada K, Kusagaya H, Kaida Y, Matsuda H, et
al: Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary
function in non-small cell lung cancer patients with and without
COPD. Int J Chron Obstruct Pulmon Dis. 14:1867–1877. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
488
|
Szejniuk WM, Nielsen MS, Brønnum D,
Takács-Szabó Z, Weinreich UM, Pilegaard Thomsen L, Bøgsted M,
Jensen I, McCulloch T, Falkmer UG, et al: Fractional exhaled nitric
oxide as a potential biomarker for radiation pneumonitis in
patients with non-small cell lung cancer: A pilot study. Clin
Transl Radiat Oncol. 19:103–109. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
489
|
Arif M, Vedamurthy BM, Choudhari R, Ostwal
YB, Mantelingu K, Kodaganur GS and Kundu TK: Nitric oxide-mediated
histone hyperacetylation in oral cancer: Target for a water-soluble
HAT inhibitor, CTK7A. Chem Biol. 17:903–913. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
490
|
Beevi SS, Rasheed AM and Geetha A:
Evaluation of oxidative stress and nitric oxide levels in patients
with oral cavity cancer. Jpn J Clin Oncol. 34:379–385. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
491
|
Korde Choudhari S, Sridharan G, Gadbail A
and Poornima V: Nitric oxide and oral cancer: A review. Oral Oncol.
48:475–483. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
492
|
Patel JB, Shah FD, Shukla SN, Shah PM and
Patel PS: Role of nitric oxide and antioxidant enzymes in the
pathogenesis of oral cancer. J Cancer Res Ther. 5:247–253. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
493
|
Brankovic B, Stanojevic G, Stojanovic I,
Veljkovic A, Kocic G, Janosevic P, Nestorovic M, Petrovic D,
Djindjic B, Pavlovic D and Krivokapic Z: Nitric oxide synthesis
modulation-a possible diagnostic and therapeutic target in
colorectal cancer. J BUON. 22:162–169. 2017.PubMed/NCBI
|
|
494
|
El-Mezayen HA, Toson el SA, Darwish H and
El-Badry E: Discriminant function based on parameters of hyaluronic
acid metabolism and nitric oxide to differentiate metastatic from
non-metastatic colorectal cancer patients. Tumour Biol.
33:995–1004. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
495
|
Gao Y, Zhou S, Pang L, Yang J, Li HJ, Huo
X and Qian SY: Celastrol suppresses nitric oxide synthases and the
angiogenesis pathway in colorectal cancer. Free Radic Res.
53:324–334. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
496
|
Gao Y, Zhou S, Xu Y, Sheng S, Qian SY and
Huo X: Nitric oxide synthase inhibitors 1400W and L-NIO inhibit
angiogenesis pathway of colorectal cancer. Nitric Oxide. 83:33–39.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
497
|
Jiang H, Verovski VN, Leonard W, Law KL,
Vermeersch M, Storme G, Van den Berge D, Gevaert T, Sermeus A and
De Ridder M: Hepatocytes determine the hypoxic microenvironment and
radiosensitivity of colorectal cancer cells through production of
nitric oxide that targets mitochondrial respiration. Int J Radiat
Oncol Biol Phys. 85:820–827. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
498
|
Krzystek-Korpacka M, Szczęśniak-Sięga B,
Szczuka I, Fortuna P, Zawadzki M, Kubiak A, Mierzchała-Pasierb M,
Fleszar MG, Lewandowski Ł, Serek P, et al: L-Arginine/Nitric oxide
pathway is altered in colorectal cancer and can be modulated by
novel derivatives from oxicam class of non-steroidal
anti-inflammatory drugs. Cancers (Basel). 12:25942020. View Article : Google Scholar : PubMed/NCBI
|
|
499
|
Liu Y, Borchert GL and Phang JM: Polyoma
enhancer activator 3, an ets transcription factor, mediates the
induction of cyclooxygenase-2 by nitric oxide in colorectal cancer
cells. J Biol Chemistry. 279:18694–18700. 2004. View Article : Google Scholar
|
|
500
|
McIlhatton MA, Tyler J, Burkholder S,
Ruschoff J, Rigas B, Kopelovich L and Fishel R: Nitric
oxide-donating aspirin derivatives suppress microsatellite
instability in mismatch repair-deficient and hereditary
nonpolyposis colorectal cancer cells. Cancer Res. 67:10966–10975.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
501
|
Moochhala S, Chhatwal VJ, Chan ST, Ngoi
SS, Chia YW and Rauff A: Nitric oxide synthase activity and
expression in human colorectal cancer. Carcinogenesis.
17:1171–1174. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
502
|
Muscat JE, Dyer AM, Rosenbaum RE and Rigas
B: Nitric oxide-releasing medications and colorectal cancer risk:
The framingham study. Anticancer Res. 25:4471–4474. 2005.PubMed/NCBI
|
|
503
|
Mandal P: Molecular signature of nitric
oxide on major cancer hallmarks of colorectal carcinoma.
Inflammopharmacology. 26:331–336. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
504
|
Yagihashi N, Kasajima H, Sugai S,
Matsumoto K, Ebina Y, Morita T, Murakami T and Yagihashi S:
Increased in situ expression of nitric oxide synthase in human
colorectal cancer. Virchows Archiv. 436:109–114. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
505
|
Yu LB, Dong XS, Sun WZ, Zhao DL and Yang
Y: Effect of a nitric oxide synthase inhibitor NG-nitro-L-arginine
methyl ester on invasion of human colorectal cancer cell line
SL-174T. World J Gastroenterol. 11:6385–6388. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
506
|
Wei B, Wei HB, Qi CL, Han XY and Wang TB:
Effect of a selective inducible nitric oxide synthase inhibitor on
cell growth in human colorectal cancer Lovo cell line. Zhonghua Wei
Chang Wai Ke Za Zhi. 11:280–283. 2008.(In Chinese). PubMed/NCBI
|
|
507
|
Siedlar M, Mytar B, Hyszko M and Zembala
M: Involvement of protein kinases in signalling for nitric oxide
(NO) and tumour necrosis factor alpha (TNF) production by monocytes
stimulated with colorectal DeTa cancer cells: The lack of evidence
for the role of TNF in the regulation of NO production. Immunol
Lett. 65:189–195. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
508
|
Atala A: Re: Alterations of tumor
microenvironment by nitric oxide impedes castration-resistant
prostate cancer growth. J Urol. 202:35–36. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
509
|
Dillioglugil MO, Mekik H, Muezzinoglu B,
Ozkan TA, Demir CG and Dillioglugil O: Blood and tissue nitric
oxide and malondialdehyde are prognostic indicators of localized
prostate cancer. Int Urol Nephrol. 44:1691–1696. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
510
|
Della Pietra E, Simonella F, Bonavida B,
Xodo LE and Rapozzi V: Repeated sub-optimal photodynamic treatments
with pheophorbide a induce an epithelial mesenchymal transition in
prostate cancer cells via nitric oxide. Nitric Oxide. 45:43–53.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
511
|
Huh J, Liepins A, Zielonka J,
Andrekopoulos C, Kalyanaraman B and Sorokin A: Cyclooxygenase 2
rescues LNCaP prostate cancer cells from sanguinarine-induced
apoptosis by a mechanism involving inhibition of nitric oxide
synthase activity. Cancer Res. 66:3726–3736. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
512
|
Lee KM, Kang D, Park SK, Berndt SI, Reding
D, Chatterjee N, Chanock S, Huang WY and Hayes RB: Nitric oxide
synthase gene polymorphisms and prostate cancer risk.
Carcinogenesis. 30:621–625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
513
|
Rezakhani L, Khazaei MR, Ghanbari A and
Khazaei M: Crab shell extract induces prostate cancer cell line
(LNcap) apoptosis and decreases nitric oxide secretion. Cell J.
19:231–237. 2017.PubMed/NCBI
|
|
514
|
Royle JS, Ross JA, Ansell I, Bollina P,
Tulloch DN and Habib FK: Nitric oxide donating nonsteroidal
anti-inflammatory drugs induce apoptosis in human prostate cancer
cell systems and human prostatic stroma via caspase-3. J Urol.
172:338–344. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
515
|
Wang D, Lu S and Dong Z: Regulation of
TGF-beta1 gene transcription in human prostate cancer cells by
nitric oxide. Prostate. 67:1825–1833. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
516
|
Tan G, Qiu M, Chen L, Zhang S, Ke L and
Liu J: JS-K, a nitric oxide pro-drug, regulates growth and
apoptosis through the ubiquitin-proteasome pathway in prostate
cancer cells. BMC Cancer. 17:3762017. View Article : Google Scholar : PubMed/NCBI
|
|
517
|
Thomas LN, Morehouse TJ and Too CK:
Testosterone and prolactin increase carboxypeptidase-D and nitric
oxide levels to promote survival of prostate cancer cells.
Prostate. 72:450–460. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
518
|
Siemens DR, Heaton JP, Adams MA, Kawakami
J and Graham CH: Phase II study of nitric oxide donor for men with
increasing prostate-specific antigen level after surgery or
radiotherapy for prostate cancer. Urology. 74:878–883. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
519
|
Soni Y, Softness K, Arora H and Ramasamy
R: The Yin yang role of nitric oxide in prostate cancer. Am J Mens
Health. 14:15579883209031912020. View Article : Google Scholar : PubMed/NCBI
|
|
520
|
Caneba CA, Yang L, Baddour J, Curtis R,
Win J, Hartig S, Marini J and Nagrath D: Nitric oxide is a positive
regulator of the Warburg effect in ovarian cancer cells. Cell Death
Dis. 5:e13022014. View Article : Google Scholar : PubMed/NCBI
|
|
521
|
El-Sehemy A, Chang AC, Azad AK, Gupta N,
Xu Z, Steed H, Karsan A and Fu Y: Notch activation augments nitric
oxide/soluble guanylyl cyclase signaling in immortalized ovarian
surface epithelial cells and ovarian cancer cells. Cell Signal.
25:2780–2787. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
522
|
El-Sehemy A, Postovit LM and Fu Y: Nitric
oxide signaling in human ovarian cancer: A potential therapeutic
target. Nitric Oxide. 54:30–37. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
523
|
Kielbik M, Klink M, Brzezinska M, Szulc I
and Sulowska Z: Nitric oxide donors: Spermine/NO and
diethylenetriamine/NO induce ovarian cancer cell death and affect
STAT3 and AKT signaling proteins. Nitric Oxide. 35:93–109. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
524
|
Leung EL, Fraser M, Fiscus RR and Tsang
BK: Cisplatin alters nitric oxide synthase levels in human ovarian
cancer cells: Involvement in p53 regulation and cisplatin
resistance. Br J Cancer. 98:1803–1809. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
525
|
Thomsen LL, Sargent JM, Williamson CJ and
Elgie AW: Nitric oxide synthase activity in fresh cells from
ovarian tumour tissue: Relationship of enzyme activity with
clinical parameters of patients with ovarian cancer. Biochem
Pharmacol. 56:1365–1370. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
526
|
Salimian Rizi B, Caneba C, Nowicka A,
Nabiyar AW, Liu X, Chen K, Klopp A and Nagrath D: Nitric oxide
mediates metabolic coupling of omentum-derived adipose stroma to
ovarian and endometrial cancer cells. Cancer Res. 75:456–471. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
527
|
Stevens EV, Carpenter AW, Shin JH, Liu J,
Der CJ and Schoenfisch MH: Nitric oxide-releasing silica
nanoparticle inhibition of ovarian cancer cell growth. Mol Pharm.
7:775–785. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
528
|
Camp ER, Yang A, Liu W, Fan F, Somcio R,
Hicklin DJ and Ellis LM: Roles of nitric oxide synthase inhibition
and vascular endothelial growth factor receptor-2 inhibition on
vascular morphology and function in an in vivo model of pancreatic
cancer. Clin Cancer Res. 12:2628–2633. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
529
|
Chen X, Jia F, Li Y, Deng Y, Huang Y, Liu
W, Jin Q and Ji J: Nitric oxide-induced stromal depletion for
improved nanoparticle penetration in pancreatic cancer treatment.
Biomaterials. 246:1199992020. View Article : Google Scholar : PubMed/NCBI
|
|
530
|
Fujita M, Imadome K, Endo S, Shoji Y,
Yamada S and Imai T: Nitric oxide increases the invasion of
pancreatic cancer cells via activation of the PI3K-AKT and RhoA
pathways after carbon ion irradiation. FEBS Lett. 588:3240–3250.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
531
|
Fujita M, Somasundaram V, Basudhar D,
Cheng RYS, Ridnour LA, Higuchi H, Imadome K, No JH, Bharadwaj G and
Wink DA: Role of nitric oxide in pancreatic cancer cells exhibiting
the invasive phenotype. Redox Biol. 22:1011582019. View Article : Google Scholar : PubMed/NCBI
|
|
532
|
Zhou H, Huang L, Sun Y and Rigas B: Nitric
oxide-donating aspirin inhibits the growth of pancreatic cancer
cells through redox-dependent signaling. Cancer Lett. 273:292–299.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
533
|
Wang B, Wei D, Crum VE, Richardson EL,
Xiong HH, Luo Y, Huang S, Abbruzzese JL and Xie K: A novel model
system for studying the double-edged roles of nitric oxide
production in pancreatic cancer growth and metastasis. Oncogene.
22:1771–1782. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
534
|
Wang L and Xie K: Nitric oxide and
pancreatic cancer pathogenesis, prevention, and treatment. Curr
Pharm Design. 16:421–427. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
535
|
Thomas WJ, Thomas DL, Knezetic JA and
Adrian TE: The role of oxygen-derived free radicals and nitric
oxide in cytokine-induced antiproliferation of pancreatic cancer
cells. Pancreas. 24:161–168. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
536
|
Stewart GD, Nanda J, Katz E, Bowman KJ,
Christie JG, Brown DJ, McLaren DB, Riddick AC, Ross JA, Jones GD
and Habib FK: DNA strand breaks and hypoxia response inhibition
mediate the radiosensitisation effect of nitric oxide donors on
prostate cancer under varying oxygen conditions. Biochem Pharmacol.
81:203–210. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
537
|
Sugita H, Kaneki M, Furuhashi S, Hirota M,
Takamori H and Baba H: Nitric oxide inhibits the proliferation and
invasion of pancreatic cancer cells through degradation of insulin
receptor substrate-1 protein. Mol Cancer Res. 8:1152–1163. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
538
|
Caygill CP, Royston C, Charlett A, Wall
CM, Gatenby PA, Ramus JR, Watson A, Winslet M, Hourigan CS and Dev
Bardhan K: Barrett's, blood groups and progression to oesophageal
cancer: Is nitric oxide the link? Eur J Gastroenterol Hepatol.
23:801–806. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
539
|
Sun GG, Hu WN, Zhang J, Li CL and Yang CR:
Effect of nitric oxide on esophageal cancer cell line TE-1. Chin
Med Sci J. 28:44–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
540
|
Gecit I, Aslan M, Gunes M, Pirincci N,
Esen R, Demir H and Ceylan K: Serum prolidase activity, oxidative
stress, and nitric oxide levels in patients with bladder cancer. J
Cancer Res Clin Oncol. 138:739–743. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
541
|
Gecit İ, Eryılmaz R, Kavak S, Meral İ,
Demir H, Pirinççi N, Güneş M and Taken K: The prolidase activity,
oxidative stress, and nitric oxide levels of bladder tissues with
or without tumor in patients with bladder cancer. J Membr Biol.
250:455–459. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
542
|
Jansson OT, Morcos E, Brundin L, Lundberg
JO, Adolfsson J, Söderhäll M and Wiklund NP: The role of nitric
oxide in bacillus Calmette-Guerin mediated anti-tumour effects in
human bladder cancer. Br J Cancer. 78:588–592. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
543
|
Kilic S, Bayraktar N, Beytur A, Ergin H,
Bayraktar M and Egri M: Can the levels of nitric oxide in the
urine, serum and tumor tissue be putative markers for bladder
cancer? Int J Urol. 13:1079–1085. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
544
|
Khalifa A, Eissa S and Aziz A:
Determination of cytosolic citrulline and nitrate as indicators of
nitric oxide in bladder cancer: Possible association with basic
fibroblast growth factor. Clin Biochem. 32:635–638. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
545
|
Morcos E, Jansson OT, Adolfsson J, Kratz G
and Wiklund NP: Endogenously formed nitric oxide modulates cell
growth in bladder cancer cell lines. Urology. 53:1252–1257. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
546
|
Wang Z, Fu S, Chen Y and Qin D: Modulation
of nitric oxide on lymphokine-activated killer cells in patients
with bladder cancer. Chin Med Sci J. 16:2132001.PubMed/NCBI
|
|
547
|
Thiel T, Ryk C, Chatzakos V, Hallén
Grufman K, Bavand-Chobot N, Flygare J, Wiklund NP and de Verdier
PJ: Secondary stimulation from Bacillus Calmette-Guerin induced
macrophages induce nitric oxide independent cell-death in bladder
cancer cells. Cancer Lett. 348:119–125. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
548
|
Saygili EI, Akcay T, Dincer Y, Obek C,
Kural AR and Cakalir C: Methylguanine DNA methyl transferase
activities, glutathione s transferase and nitric oxide in bladder
cancer patients. Cancer Invest. 24:256–260. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
549
|
Bakan E, Taysi S, Polat MF, Dalga S,
Umudum Z, Bakan N and Gumus M: Nitric oxide levels and lipid
peroxidation in plasma of patients with gastric cancer. Jap J Clin
Oncol. 32:162–166. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
550
|
Dincer Y, Akcay T, Tortum OB and Dogusoy
G: Nitric oxide and antioxidant defense in patients with gastric
cancer. Dig Dis Sci. 51:1367–1370. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
551
|
Holian O, Wahid S, Atten MJ and Attar BM:
Inhibition of gastric cancer cell proliferation by resveratrol:
Role of nitric oxide. Am J Physiol Gastrointest Liver Physiol.
282:G809–G816. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
552
|
Eroğlu A, Demirci S, Ayyildiz A, Kocaoğlu
H, Akbulut H, Akgül H and Elhan HA: Serum concentrations of
vascular endothelial growth factor and nitrite as an estimate of in
vivo nitric oxide in patients with gastric cancer. Br J Cancer.
80:1630–1634. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
553
|
Koh E, Noh SH, Lee YD, Lee HY, Han JW, Lee
HW and Hong S: Differential expression of nitric oxide synthase in
human stomach cancer. Cancer Lett. 146:173–180. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
554
|
Oshima T, Imada T, Nagashima Y, Cho H,
Shiozawa M, Rino Y and Takanashi Y: Role of nitric oxide in human
gastric cancer cells treated with 5-fluorouracil. Oncol Rep.
8:847–849. 2001.PubMed/NCBI
|
|
555
|
Rajnakova A, Goh PM, Chan ST, Ngoi SS,
Alponat A and Moochhala S: Expression of differential nitric oxide
synthase isoforms in human normal gastric mucosa and gastric cancer
tissue. Carcinogenesis. 18:1841–1845. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
556
|
Yao X, Wu Y, Zhu M, Qian H and Chen Y:
Nitric oxide/cyclic guanosine monophosphate inducers sodium
nitroprusside and L-arginine inhibit the proliferation of gastric
cancer cells via the activation of type II cyclic guanosine
monophosphate-dependent protein kinase. Oncol Lett. 10:479–484.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
557
|
Sang J, Chen Y and Tao Y: Nitric oxide
inhibits gastric cancer cell growth through the modulation of the
Akt pathway. Mol Med Rep. 4:1163–1167. 2011.PubMed/NCBI
|
|
558
|
Sang JR, Chen YC, Shao GB and Huang XJ:
Effect of nitric oxide on the proliferation of AGS gastric cancer
cells. Chin J Cancer. 29:158–162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
559
|
Li YH, Guo M, Shi SW, Zhang QL, Yang SP
and Liu JG: A ruthenium-nitrosyl-functionalized nanoplatform for
the targeting of liver cancer cells and NIR-light-controlled
delivery of nitric oxide combined with photothermal therapy. J
Mater Chem B. 5:7831–7838. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
560
|
Muntane J, De la Rosa AJ, Marin LM and
Padillo FJ: Nitric oxide and cell death in liver cancer cells.
Mitochondrion. 13:257–262. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
561
|
Sayed-Ahmad MM and Mohamad MA:
Contribution of nitric oxide and epidermal growth factor receptor
in anti-metastatic potential of paclitaxel in human liver cancer
cell (HebG2). J Egypt Natl Canc Inst. 17:35–41. 2005.PubMed/NCBI
|
|
562
|
Li J, Rao H, Jin C and Liu J: Involvement
of the Toll-like receptor/Nitric oxide signaling pathway in the
pathogenesis of cervical cancer caused by high-risk human
papillomavirus infection. Biomed Res Int.
2017:78302622017.PubMed/NCBI
|
|
563
|
Park IC, Woo SH, Park MJ, Lee HC, Lee SJ,
Hong YJ, Lee SH, Hong SI and Rhee CH: Ionizing radiation and nitric
oxide donor sensitize Fas-induced apoptosis via up-regulation of
Fas in human cervical cancer cells. Oncol Rep. 10:629–633.
2003.PubMed/NCBI
|
|
564
|
Wei XM, Wang Q, Gao SJ and Sui L:
Relationship between nitric oxide in cervical microenvironment and
different HPV types and effect on cervical cancer cells. Zhonghua
Fu Chan Ke Za Zhi. 46:260–265. 2011.(In Chinese). PubMed/NCBI
|
|
565
|
Sudhesh P, Tamilarasan K, Arumugam P and
Berchmans S: Nitric oxide releasing photoresponsive nanohybrids as
excellent therapeutic agent for cervical cancer cell lines. ACS
Appl Mater Interfaces. 5:8263–8266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
566
|
Sundaram MK, Khan MA, Alalami U, Somvanshi
P, Bhardwaj T, Pramodh S, Raina R, Shekfeh Z, Haque S and Hussain
A: Phytochemicals induce apoptosis by modulation of nitric oxide
signaling pathway in cervical cancer cells. Eur Rev Med Pharmacol
Sci. 24:11827–11844. 2020.PubMed/NCBI
|
|
567
|
Menendez L, Juarez L, Garcia V, Hidalgo A
and Baamonde A: Involvement of nitric oxide in the inhibition of
bone cancer-induced hyperalgesia through the activation of
peripheral opioid receptors in mice. Neuropharmacology. 53:71–80.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
568
|
Yang Y, Zhang J, Liu Y, Zheng Y, Bo J,
Zhou X, Wang J and Ma Z: Role of nitric oxide synthase in the
development of bone cancer pain and effect of L-NMMA. Mol Med Rep.
13:1220–1226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
569
|
Giusti M, Valenti S, Guazzini B, Molinari
E, Cavallero D, Augeri C and Minuto F: Circulating nitric oxide is
modulated by recombinant human TSH administration during monitoring
of thyroid cancer remnant. J Endocrinol Invest. 26:1192–1197. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
570
|
Ragot T, Provost C, Prignon A, Cohen R,
Lepoivre M and Lausson S: Apoptosis induction by combination of
drugs or a conjugated molecule associating non-steroidal
anti-inflammatory and nitric oxide donor effects in medullary
thyroid cancer models: Implication of the tumor suppressor p73.
Thyroid Res. 8:132015. View Article : Google Scholar : PubMed/NCBI
|
|
571
|
Gallo O, Masini E, Morbidelli L, Franchi
A, Fini-Storchi I, Vergari WA and Ziche M: Role of nitric oxide in
angiogenesis and tumor progression in head and neck cancer. J Natl
Cancer Inst. 90:587–596. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
572
|
Kawakami K, Kawakami M and Puri RK: Nitric
oxide accelerates interleukin-13 cytotoxin-mediated regression in
head and neck cancer animal model. Clin Cancer Res. 10:5264–5270.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
573
|
Wu HL, Chu YH, Tai YH, Tsou MY, Wu CH, Lo
WL, Tai SK, Yeh CC and Lu CC: Stage-dependent angiopoietin-Tie2 and
nitric oxide signaling of erythrocytes in response to surgical
trauma in head and neck cancer. World J Surg Oncol. 18:2092020.
View Article : Google Scholar : PubMed/NCBI
|
|
574
|
Utispan K and Koontongkaew S: High nitric
oxide adaptation in isogenic primary and metastatic head and neck
cancer cells. Anticancer Res. 40:2657–2665. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
575
|
Taysi S, Uslu C, Akcay F and Sutbeyaz MY:
Malondialdehyde and nitric oxide levels in the plasma of patients
with advanced laryngeal cancer. Surg Today. 33:651–654. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
576
|
Sanhueza C, Araos J, Naranjo L, Barros E,
Subiabre M, Toledo F, Gutiérrez J, Chiarello DI, Pardo F, Leiva A
and Sobrevia L: Nitric oxide and pH modulation in gynaecological
cancer. J Cell Mol Med. 20:2223–2230. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
577
|
Chattopadhyay M, Kodela R, Nath N,
Barsegian A, Boring D and Kashfi K: Hydrogen sulfide-releasing
aspirin suppresses NF-κB signaling in estrogen receptor negative
breast cancer cells in vitro and in vivo. Biochem Pharmacol.
83:723–732. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
578
|
Dong Q, Yang B, Han JG, Zhang MM, Liu W,
Zhang X, Yu HL, Liu ZG, Zhang SH, Li T, et al: A novel hydrogen
sulfide-releasing donor, HA-ADT, suppresses the growth of human
breast cancer cells through inhibiting the PI3K/AKT/mTOR and
Ras/Raf/MEK/ERK signaling pathways. Cancer Lett. 455:60–72. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
579
|
Li Y, Zhou J, Wang L and Xie Z: Endogenous
hydrogen sulfide-triggered MOF-based nanoenzyme for synergic cancer
therapy. ACS Appl Mater Interfaces. 12:30213–30220. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
580
|
Lv M, Li Y, Ji MH, Zhuang M and Tang JH:
Inhibition of invasion and epithelial-mesenchymal transition of
human breast cancer cells by hydrogen sulfide through decreased
phospho-p38 expression. Mol Med Rep. 10:341–346. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
581
|
Choi KS, Song H, Kim EH, Choi JH, Hong H,
Han YM and Hahm KB: Inhibition of Hydrogen Sulfide-induced
angiogenesis and inflammation in vascular endothelial cells:
Potential mechanisms of gastric cancer prevention by korean red
ginseng. J Ginseng Res. 36:135–145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
582
|
Kawahara Y, Hirashita Y, Tamura C, Kudo Y,
Sakai K, Togo K, Fukuda K, Matsunari O, Okamoto K, Ogawa R, et al:
Helicobacter pylori infection modulates endogenous hydrogen
sulfide production in gastric cancer AGS cells. Helicobacter.
25:e127322020. View Article : Google Scholar : PubMed/NCBI
|
|
583
|
Sekiguchi F, Sekimoto T, Ogura A and
Kawabata A: Endogenous hydrogen sulfide enhances cell proliferation
of human gastric cancer AGS cells. Biol Pharm Bull. 39:887–890.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
584
|
Wang R, Tao B, Fan Q, Wang S, Chen L,
Zhang J, Hao Y, Dong S, Wang Z, Wang W, et al: Fatty-acid receptor
CD36 functions as a hydrogen sulfide-targeted receptor with its
Cys333-Cys272 disulfide bond serving as a specific molecular switch
to accelerate gastric cancer metastasis. EBioMedicine. 45:108–123.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
585
|
Ye F, Li X, Sun K, Xu W, Shi H, Bian J, Lu
R and Ye Y: Inhibition of endogenous hydrogen sulfide biosynthesis
enhances the anti-cancer effect of 3,3′-diindolylmethane in human
gastric cancer cells. Life Sci. 261:1183482020. View Article : Google Scholar : PubMed/NCBI
|
|
586
|
Chen S, Yue T, Huang Z, Zhu J, Bu D, Wang
X, Pan Y, Liu Y and Wang P: Inhibition of hydrogen sulfide
synthesis reverses acquired resistance to 5-FU through
miR-215-5p-EREG/TYMS axis in colon cancer cells. Cancer Lett.
466:49–60. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
587
|
Cai WJ, Wang MJ, Ju LH, Wang C and Zhu YC:
Hydrogen sulfide induces human colon cancer cell proliferation:
Role of Akt, ERK and p21. Cell Biol Int. 34:565–572. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
588
|
Hale VL, Jeraldo P, Mundy M, Yao J, Keeney
G, Scott N, Cheek EH, Davidson J, Greene M, Martinez C, et al:
Synthesis of multi-omic data and community metabolic models reveals
insights into the role of hydrogen sulfide in colon cancer.
Methods. 149:59–68. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
589
|
Hong M, Tang X and He K: Effect of
hydrogen sulfide on human colon cancer SW480 cell proliferation and
migration in vitro. Nan Fang Yi Ke Da Xue Xue Bao. 34:699–703.
2014.(In Chinese). PubMed/NCBI
|
|
590
|
Kodela R, Nath N, Chattopadhyay M, Nesbitt
DE, Velázquez-Martínez CA and Kashfi K: Hydrogen sulfide-releasing
naproxen suppresses colon cancer cell growth and inhibits NF-κB
signaling. Drug Design Dev Ther. 9:4873–4882. 2015.PubMed/NCBI
|
|
591
|
Chen S, Wang P and Liu Y: Research
progress of the association of hydrogen sulfide with colorectal
cancer and its associated anti-tumor drugs. Zhonghua Wei Chang Wai
Ke Za Zhi. 20:834–840. 2017.(In Chinese). PubMed/NCBI
|
|
592
|
Elsheikh W, Blackler RW, Flannigan KL and
Wallace JL: Enhanced chemopreventive effects of a hydrogen
sulfide-releasing anti-inflammatory drug (ATB-346) in experimental
colorectal cancer. Nitric Oxide. 41:131–137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
593
|
Faris P, Ferulli F, Vismara M, Tanzi M,
Negri S, Rumolo A, Lefkimmiatis K, Maestri M, Shekha M, Pedrazzoli
P, et al: Hydrogen Sulfide-evoked intracellular Ca2+
signals in primary cultures of metastatic colorectal cancer cells.
Cancers (Basel). 12:33382020. View Article : Google Scholar : PubMed/NCBI
|
|
594
|
Malagrinò F, Zuhra K, Mascolo L,
Mastronicola D, Vicente JB, Forte E and Giuffrè A: Hydrogen sulfide
oxidation: Adaptive changes in mitochondria of SW480 colorectal
cancer cells upon exposure to hypoxia. Oxid Med Cell Longev.
2019:81029362019. View Article : Google Scholar : PubMed/NCBI
|
|
595
|
Sakuma S, Minamino S, Takase M, Ishiyama
Y, Hosokura H, Kohda T, Ikeda Y and Fujimoto Y: Hydrogen sulfide
donor GYY4137 suppresses proliferation of human colorectal cancer
Caco-2 cells by inducing both cell cycle arrest and cell death.
Heliyon. 5:e022442019. View Article : Google Scholar : PubMed/NCBI
|
|
596
|
Liu H, Chang J, Zhao Z, Li Y and Hou J:
Effects of exogenous hydrogen sulfide on the proliferation and
invasion of human Bladder cancer cells. J Cancer Res Ther.
13:829–832. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
597
|
Liu M, Wu L, Montaut S and Yang G:
Hydrogen sulfide signaling axis as a target for prostate cancer
therapeutics. Prostate Cancer. 2016:81085492016. View Article : Google Scholar : PubMed/NCBI
|
|
598
|
Zhang S, Bian H, Li X, Wu H, Bi Q, Yan Y
and Wang Y: Hydrogen sulfide promotes cell proliferation of oral
cancer through activation of the COX2/AKT/ERK1/2 axis. Oncol Rep.
35:2825–2832. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
599
|
Zhuang L, Li K, Wang G, Shou T, Gao C, Mao
Y, Bao M and Zhao M: Preconditioning with hydrogen sulfide prevents
bone cancer pain in rats through a proliferator-activated receptor
gamma/p38/Jun N-terminal kinase pathway. Exp Biol Med (Maywood).
243:57–65. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
600
|
Xu Y, Ma N, Wei P, Zeng Z and Meng J:
Expression of hydrogen sulfide synthases and Hh signaling pathway
components correlate with the clinicopathological characteristics
of papillary thyroid cancer patients. Int J Clin Exp Pathol.
11:1818–1824. 2018.PubMed/NCBI
|
|
601
|
Huang CC, Ho CH, Chen YC, Hsu CC, Lin HJ,
Tian YF, Wang JJ and Guo HR: Impact of carbon monoxide poisoning on
the risk of breast cancer. Sci Rep. 10:204502020. View Article : Google Scholar : PubMed/NCBI
|
|
602
|
Kawahara B, Moller T, Hu-Moore K,
Carrington S, Faull KF, Sen S and Mascharak PK: Attenuation of
antioxidant capacity in human breast cancer cells by carbon
monoxide through inhibition of cystathionine β-synthase activity:
Implications in chemotherapeutic drug sensitivity. J Med Chem.
60:8000–8010. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
603
|
Kim DH, Yoon HJ, Cha YN and Surh YJ: Role
of heme oxygenase-1 and its reaction product, carbon monoxide, in
manifestation of breast cancer stem cell-like properties: Notch-1
as a putative target. Free Radical Res. 52:1336–1347. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
604
|
Kourti M, Westwell A, Jiang W and Cai J:
Repurposing old carbon monoxide-releasing molecules towards the
anti-angiogenic therapy of triple-negative breast cancer.
Oncotarget. 10:1132–1148. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
605
|
Lee WY, Chen YC, Shih CM, Lin CM, Cheng
CH, Chen KC and Lin CW: The induction of heme oxygenase-1
suppresses heat shock protein 90 and the proliferation of human
breast cancer cells through its byproduct carbon monoxide. Toxicol
Appl Pharmacol. 274:55–62. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
606
|
Kawahara B, Gao L, Cohn W, Whitelegge JP,
Sen S, Janzen C and Mascharak PK: Diminished viability of human
ovarian cancer cells by antigen-specific delivery of carbon
monoxide with a family of photoactivatable antibody-photoCORM
conjugates. Chem Sci. 11:467–473. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
607
|
Kawahara B, Ramadoss S, Chaudhuri G,
Janzen C, Sen S and Mascharak PK: Carbon monoxide sensitizes
cisplatin-resistant ovarian cancer cell lines toward cisplatin via
attenuation of levels of glutathione and nuclear metallothionein. J
Inorganic Biochem. 191:29–39. 2019. View Article : Google Scholar
|
|
608
|
Khasag N, Sakiyama S, Toba H, Yoshida M,
Nakagawa Y, Takizawa H, Kawakami Y, Kenzaki K, Ali AH, Kondo K and
Tangoku A: Monitoring of exhaled carbon monoxide and carbon dioxide
during lung cancer operation. Eur J Cardiothorac Surg. 45:531–536.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
609
|
Liptay MJ, Basu S, Hoaglin MC, Freedman N,
Faber LP, Warren WH, Hammoud ZT and Kim AW: Diffusion lung capacity
for carbon monoxide (DLCO) is an independent prognostic factor for
long-term survival after curative lung resection for cancer. J Surg
Oncol. 100:703–707. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
610
|
Nemeth Z, Csizmadia E, Vikstrom L, Li M,
Bisht K, Feizi A, Otterbein S, Zuckerbraun B, Costa DB, Pandolfi
PP, et al: Alterations of tumor microenvironment by carbon monoxide
impedes lung cancer growth. Oncotarget. 7:23919–23932. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
611
|
Shao L, Gu YY, Jiang CH, Liu CY, Lv LP,
Liu JN and Zou Y: Carbon monoxide releasing molecule-2 suppresses
proliferation, migration, invasion, and promotes apoptosis in
non-small cell lung cancer Calu-3 cells. Eur Rev Med Pharmacol Sci.
22:1948–1957. 2018.PubMed/NCBI
|
|
612
|
Shirabe T, Mawatari S and Kuroiwa Y:
Autopsy case of carbon monoxide poisoning at the Miike Coal Mine
explosion-a case of lung cancer with the fatal outcome in 3 years
and 4 months. Shinkei Kenkyu No Shimpo. 14:321–326. 1970.PubMed/NCBI
|
|
613
|
Zarogoulidis P, Kerenidi T, Huang H,
Kontakiotis T, Tremma O, Porpodis K, Kalianos A, Rapti A, Foroulis
C, Zissimopoulos A, et al: Six minute walking test and carbon
monoxide diffusing capacity for non-small cell lung cancer: Easy
performed tests in every day practice. J Thorac Dis. 4:569–576.
2012.PubMed/NCBI
|
|
614
|
Lian S, Xia Y, Ung TT, Khoi PN, Yoon HJ,
Kim NH, Kim KK and Jung YD: Carbon monoxide releasing molecule-2
ameliorates IL-1β-induced IL-8 in human gastric cancer cells.
Toxicology. 361–362. 24–38. 2016.PubMed/NCBI
|
|
615
|
Lv C, Su Q, Fang J and Yin H:
Styrene-maleic acid copolymer-encapsulated carbon monoxide
releasing molecule-2 (SMA/CORM-2) suppresses proliferation,
migration and invasion of colorectal cancer cells in vitro and in
vivo. Biochem Biophys Res Commun. 520:320–326. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
616
|
Yin H, Fang J, Liao L, Maeda H and Su Q:
Upregulation of heme oxygenase-1 in colorectal cancer patients with
increased circulation carbon monoxide levels, potentially affects
chemotherapeutic sensitivity. BMC Cancer. 14:4362014. View Article : Google Scholar : PubMed/NCBI
|
|
617
|
Nitta S, Kawai K, Nagumo Y, Ikeda A,
Kandori S, Kojima T and Nishiyama H: Impact of hemoglobin levels on
hemoglobin-adjusted carbon monoxide diffusion capacity after
chemotherapy for testicular cancer. Jpn J Clin Oncol. 49:1151–1156.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
618
|
van Osch FHM, Pauwels CGGM, Jochems SHJ,
Fayokun R, James ND, Wallace DMA, Cheng KK, Bryan RT, van Schooten
FJ and Zeegers MP: Tar, nicotine and carbon monoxide yield of UK
cigarettes and the risk of non-muscle-invasive and muscle-invasive
bladder cancer. Eur J Cancer Prev. 28:40–44. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
619
|
Vítek L, Gbelcová H, Muchová L, Váňová K,
Zelenka J, Koníčková R, Suk J, Zadinova M, Knejzlík Z, Ahmad S, et
al: Antiproliferative effects of carbon monoxide on pancreatic
cancer. Dig Liver Dis. 46:369–375. 2014. View Article : Google Scholar : PubMed/NCBI
|
